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ABSTRACT
THE ROLE OF ARX IN SPECIFICATION AND MAINTENANCE OF
PANCREATIC ISLET α-CELLS
Crystal L. Wilcox
Catherine L. May, Ph.D.

Correct specification and maintenance of pancreatic islet cells is an intricate process.
Previous studies have demonstrated the essential role transcription factors play in this
process. For islet glucagon-producing α-cells one such transcription factor is the
aristaless-related homeobox gene (Arx). Previous studies have demonstrated that Arx is
necessary and sufficient for α-cell specification where ablation of Arx results in complete
loss of the α-cell lineage and misexpression leads to conversion into an α-cell phenotype.
However, the role of Arx in maintenance of α-cell fate as well the impact non-null
mutations of Arx have on α-cell development has not been explored. In this dissertation,
I utilize mouse models and pancreatic analysis to address this question. My results
demonstrate that Arx is necessary to maintain α-cell fate during development as well as
in the adult. Furthermore, analysis of a non-null expansion mutation of Arx suggests dual
roles for this factor during α-cell specification in activation of α-cell fate and repression
of non-α-cell fate. These findings expand the role of Arx in the islet α-cell as well as
provide an attractive avenue for future therapies for type II diabetes.
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CHAPTER I:

INTRODUCTION

1

The pancreas is a two-component organ responsible for maintaining glucose
homeostasis and digesting nutrients.
The pancreas is an organ situated between the stomach and intestine composed of
three tissue types: exocrine, endocrine, and ductal [1]. The exocrine portion of the
pancreas makes up the majority of pancreatic mass [2]. It is comprised of acinar cells,
which secrete digestive enzymes utilized in the duodenum of the digestive tract [2]. The
endocrine portion of the pancreas, organized into small spheres called Islets of
Langerhans, is responsible for producing and secreting hormones responsible for glucose
homeostasis [1]. The ductal system of the pancreas is a series of tubes that connects the
exocrine acinar cells to the duodenum of the intestine [1].
During embryogenesis dorsal and ventral evagination of the foregut endoderm
occurs resulting in the formation of the dorsal and ventral pancreatic buds [3]. This event
takes place at approximately embryonic day (E)9.5 for the dorsal bud and a day later for
the ventral bud (Fig 1.1) [4]. Initially, the pancreas grows as two separate buds
influenced by distinct signals from the surrounding tissues and transcriptional regulators
[4]. During mid-gestation, these buds undergo branching morphogenesis and
differentiation to form the mature pancreas containing the three major cell types [4].
Before birth, the ventral portion of the pancreas rotates around the gut to fuse with the
dorsal portion, thereby forming the final pancreatic structure (Fig 1.1) [1].
Pancreatic development is organized into two transitions during embryogenesis
(Fig. 1.1). The primary transition begins with the budding of the dorsal pancreas around
2

E9.5 [3]. The initial set-up of the pancreatic epithelium defines this period [3]. The
secondary transition occurs between E13.5 and E15.5 and is marked by a peak of
endocrine and exocrine proliferation and expansion [3]. During this time the exocrine
acinar cells expand exponentially and begin to produce digestive enzymes [3]. In the
endocrine compartment, the secondary transition is when the principal endocrine cells are
formed and migrate to form the Islets of Langerhans [3].
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Figure 1.1: Primary and Secondary Transitions of Pancreatic Development

4

Figure 1.1: Primary and Secondary Transitions of Pancreatic Development. A
schematic diagram depicting embryonic pancreas development. Around E9.5 dorsal and
ventral pancreatic buds develop from the foregut/midgut junction of the definitive
endoderm. The dorsal bud develops first, followed a day later by the ventral bud. The
initial budding, proliferation, and set-up of the pancreatic structure define the primary
transition. The secondary transition consists of a wave of exocrine and endocrine cellular
proliferation. Finally, at ~E18, the ventral bud rotates around the gut and fuses with the
dorsal bud to create the final pancreatic structure.
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The endocrine Islets of Langerhans produce and secrete hormones responsible for
glucose homeostasis.
The Islets of Langerhans contain five cell types: α, β, δ, PP, and ε [1]. Murine
islets are comprised of a core of insulin producing β-cells with a surrounding mantle of α, δ-, PP-, and ε-cells, which synthesize the hormones glucagon, somatostatin, Pancreatic
Polypeptide, and ghrelin, respectively (Fig 1.2A) [1].
During the primary transition a few glucagon+ and insulin+ cells are present [5].
However, these cells do not contribute to the functional compartment of the endocrine
pancreas [6]. The principal endocrine cells develop during the secondary transition. All
endocrine cells are derived from a common endocrine progenitor population that is
Neurogenin3+ (Ngn3+) [7]. Endocrine cells, first formed in the developing pancreatic
ducts, undergo an endoderm-mesoderm transition to migrate into the surrounding acinar
tissue and form the Islets of Langerhans [7]. This process begins during the secondary
transition and is completed within the first two weeks of life [7].
The endocrine pancreas is responsible for glucose homeostasis, which is achieved
through the converse actions of β- and α-cells secreting the hormones insulin and
glucagon, respectively [8]. After ingestion of food, blood glucose levels rise and β-cells
begin to secrete insulin [8]. Insulin signals to the skeletal muscle and adipose tissue to
metabolize and store glucose, removing it from the blood stream, and consequently
reducing blood glucose levels (Fig 1.2B) [8]. Conversely, during a period of fasting,
such as sleep, blood glucose levels fall [9]. To maintain blood glucose levels during a
6

fasted state, glucagon is secreted from the pancreatic α-cells [9]. Glucagon signals to the
liver to break down stored glucose and release it into the blood stream through the
process of gluconeogenesis and glycogenolysis, resulting in a rise in blood glucose levels
[10]. Together, these two hormones maintain proper blood glucose homeostasis.

7

Figure 1.2: The Islets of Langerhans are composed of five different cell types and
control blood glucose homeostasis.
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Figure 1.2: The Islets of Langerhans are composed of five different cell types and
control blood glucose homeostasis. (A): Murine Islets of Langerhans are comprised of
five cell types: a core of insulin-producing β-cells (blue) with a surrounding mantle of
glucagon-producing α-cells (red), somatostatin-producing δ-cells (purple), Pancreatic
Polypeptide-producing PP-cells (green), and ghrelin-producing ε-cells (orange). (B): The
converse actions of glucagon-producing α-cells and insulin-producing β-cells maintain
glucose homeostasis. Under conditions of high blood glucose, β-cells secrete insulin,
which causes uptake and storage of glucose and a concomitant decrease in blood glucose
levels. Conversely, when blood glucose levels fall too low, α-cells secrete glucagon,
resulting in the breakdown of stored energy and increased blood glucose levels.

9

Loss of normal glucose homeostasis results in the metabolic syndrome diabetes
mellitus.
Diabetes mellitus is a metabolic syndrome characterized by the loss of normal
glucose homeostasis leading to consistently elevated blood glucose levels, even during
periods of fasting [11]. Clinically, there are two forms of diabetes, type I and type II.
Type I, or juvenile diabetes, results from the loss of endocrine β-cells via an autoimmune
attack [12]. Type II diabetes is the most common form of the disease and is the product of
insulin resistance and β-cell dysfunction [12]. In type II diabetes, β-cells become
exhausted and can no longer produce enough insulin to properly lower blood glucose
levels [12].
In correlation with the rise in obesity, the incidence of type II diabetes over the
past few decades has skyrocketed [13]. Currently, 8.3% of the United States population
has been diagnosed with some form of diabetes, which translates into 25.8 million adults
and children [13]. Furthermore, there are 1.9 million new cases each year [13]. Diabetes
has a deleterious influence on overall health, including negative impacts on a patient’s
vision (glaucoma and cataracts), circulation (hypertension and neuropathy), skin
(infections and inflammation), mental health, hearing, teeth (gum disease), stomach
(gastroparesis), and kidneys (ketoacidosis and nephropathy), as well as dramatically
increasing risk of stroke and heart attack [13]. Overall, diabetes and its related
complications cost the United States $245 billion in 2012, making diabetes a global
health crisis [13].
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Recently, a new model underlying the clinical presentation of diabetes has been
proposed. This new mechanism focuses on a bihormonal view of the disease,
encompassing not only β-cell exhaustion and lack of insulin release, but also α-cell
dysregulation and over secretion of glucagon [10]. In this model, β-cell exhaustion leads
to loss of proper signaling to glucagon-producing α-cells [10]. This results in
deregulation of α-cells, over secretion of glucagon, and further increases in blood glucose
levels [14]. Additionally, continual glucagon release makes attempts to reduce blood
glucose levels less effective, further compounding the problem [14].
The bihormonal view of diabetes suggests that loss of proper glucose homeostasis
results from dysregulation of the entire endocrine pancreas, not just lost β-cell function
and insulin secretion [10]. Thus, treatments aimed at increasing β-cell mass or function
while decreasing α-cell mass/function would be extremely effective at obtaining blood
glucose control [15]. Most therapies only focus on increasing insulin content, while
largely ignoring the effect of glucagon in these patients, rendering current therapies
largely ineffective [15]. Thus, novel treatments addressing both sides of the bihormonal
theory of diabetes are essential.
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Novel treatments for diabetes focus on in vivo replacement of β-cells.
Currently, exogenous insulin administration through daily subcutaneous injections
is the most common treatment for Type I and II diabetes (Fig 1.3) [13]. While this
treatment addresses the most pressing hallmark of diabetes, high blood glucose levels and
reduced insulin secretion, it contains several inherent flaws. First, exogenous
administration of insulin does not contain the same degree of control as endogenous βcell sensing and insulin release. This lack of control requires constant blood glucose
monitoring to ensure adequate insulin is administered to control blood glucose levels
[13]. Second, exogenous insulin administration places patients at risk for severe and
potentially life-threatening periods of hypoglycemia [16]. If insulin levels are forced too
high this could cause blood glucose levels to fall dangerously low. Finally, exogenous
insulin administration does not address the long-term problem of β-cell loss or
dysfunction. Continual adjustment of insulin administration and dosage is necessary to
combat insulin resistance and deteriorating blood glucose homeostasis [13]. New
treatments that provide a finer degree of control and are more suitable for long-term use
are critical, given the large percentage of the world population that suffers from some
form of diabetes.
A novel treatment for type II diabetes has recently moved into clinical
development: islet transplantation. Islets are isolated from multiple donors, pooled, and
transplanted into the portal vein of the liver where the islets attach to the walls of the vein
[17]. Clinical trials have demonstrated success at reducing blood glucose levels and
improving diabetic patient outcomes utilizing this approach [17]. However, there are
12

multiple drawbacks to islet transplantation. Islets, especially β-cells, are sensitive to the
immunosuppressants necessary for this procedure [17]. Furthermore, studies have
demonstrated that transplanted islets have a finite life span of only five years before a
patient requires either supplemental therapy or another transplant [17]. Additionally,
multiple donors (usually 2-3) are necessary to obtain enough islets for a successful
transplantation [17]. Overall, the current state of islet transplantation deems it unfeasible
for large-scale use in treating Type II diabetes. New developments in prolonging islet
life as well as improved harvesting methods might make this treatment a more attractive
option in the future.
A different take on the concept of β-cell replacement is the use of embryonic stem
cells (ESCs) or induced pluripotent stem cells (iPS) to generate β-cells in vitro. ESCs are
cells with unlimited differentiation potential originally derived from human blastocysts
[18]. These cells are maintained in culture and, using the correct developmental signals,
can be directed into any mature cell type [18]. Thus, ESCs can theoretically be used to
create functional, mature β-cells [18]. In contrast to the finite supply available for islet
transplantation, creation of new β-cells in a laboratory setting would yield a theoretically
unlimited β-cell population and make transplantation procedures more feasible [18].
A variation on this method is the use of induced pluripotent stem cells (iPS cells).
iPS cells are mature cells that are converted back into a stem-like fate [19]. These iPS
cells can then be differentiated into a different mature cell type using the same
technology as for ESCs [19]. The benefit of using iPS cells over ESCs is that iPS cells
can be made from non-pancreatic tissue from the donor and thus be matched to the
13

recipient, eliminating the need for harmful and expensive immunosuppressive therapies
(Fig 1.3) [19].
These stem cell based therapies have multiple obstacles, including lack of cellular
homogeneity, inability to correctly differentiate, and questions regarding patient safety
[19]. Neither the ESC or iPS fields have been able to produce mature β-cells that
correctly respond to insulin in an in vitro setting [19]. Studies that have managed to
make β-like cells report very low yield of potential β-cells from the starting stem cell
population [20]. In fact, the majority of cells created are not β-cells, but rather are some
other pancreatic or endoderm cell [20]. Finally, even if mature β-cells can be produced,
they will require years of testing to ensure these cells do not become malignant once
transplanted into recipient tissue [19]. Overall, while promising, these therapies are most
likely decades away from being a treatment option for diabetic patients in a clinical
setting.
Another very attractive therapy for type I and II diabetes is the use of
transdifferentiation to create new β-cells in vivo [19]. This treatment involves altering
the identity of other endogenous cells, typically pancreatic cell types, into a β-cell fate
either through the loss or misexpression of specific proteins [19]. In vivo and in vitro
studies have demonstrated that pancreatic cell types are relatively plastic and can be
directed into a β-like-fate [21]. With the development of the bihormonal theory of
diabetes, use of endogenous α-cells to create new β-cells in vivo has become a very
appealing option [19]. Transdifferentiation of α-cells would address the bihormonal
theory of diabetes by decreasing the number of glucagon-producing α-cells while
14

increasing the number of insulin-producing β-cells. This would provide an ideal longterm therapy for type I and II diabetic patients (Fig 1.3).
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Figure 1.3: Current and novel treatment options for Type I and II diabetes
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Figure 1.3: Current and novel treatment options for Type I and II diabetes. Flow
chart depicting current (left most red box) and novel treatments (middle and right-most
red boxes) for type I and type II diabetes. Current therapies focus on exogenous insulin
replacement or boosting β-cell function (left most red box). New therapies currently in
clinical development include islet transplantation (right most red box). Future therapies
focus on the generation of new β-cells (center red box) either through ESC/iPS
differentiation (left purple box) or transdifferentiation of other endogenous cell types
(right purple box).
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Transcription Factors Are Essential for Proper Pancreatic Endocrine Specification
and Maintenance.
In order to develop novel therapies to treat diabetes, knowledge of normal
endocrine cell development and maintenance is critical. Decades of research have
demonstrated that broadly expressed (i.e. Ldb1) and cell type specific (i.e. Pdx1, etc)
transcription factors are essential for the proper specification and maintenance of
pancreatic endocrine cells [2].
Transcription factors are proteins that bind to DNA and activate or repress
specific transcriptional programs [22]. In the endocrine pancreas, these factors are first
expressed in Ngn3+ endocrine progenitors, in which they act to narrow and define cell
fate [7]. In turn these transcription factors turn on other cell-type specific proteins,
eventually leading to the correct transcriptional program for each discrete endocrine cell
population (Fig 1.4A) [7]. The transcriptional control of pancreatic endocrine cell
specification has been most extensively studied in β-cells. Three examples of β-cell
specific transcription factors that are essential for correct specification and/or
maintenance are Pdx1, Pax4, and MafA (Fig 1.4B).
Pdx1 is one of the first transcription factors expressed in the embryonic pancreas,
starting at approximately E8.5 [23]. Expression originates in the entire pancreatic
epithelium, but is eventually restricted to β- and δ-cells where it is expressed in the
mature pancreas [24]. Ablation of Pdx1 early in development results in agenesis of the
pancreas (Fig 1.4B) [23]. Additionally, a β-cell specific ablation of Pdx1 during
18

development results in a drastic reduction in the number of β-cells [24]. Finally, in the
mature pancreas Pdx1 is essential for proper maintenance of β-cell function [25].
Ablation of Pdx1 in mature β-cells leads to loss of proper insulin signaling and
eventually, apoptosis [25].
Another transcription factor important in β-cell specification and development is
Pax4. Pax4 expression is seen at E9.5 in both pancreatic buds, but is restricted to β-cells
after E15 [26]. Ablation of Pax4 in the developing pancreas results in loss of β- and δcells with a concomitant increase in α- and ε-cell fates (Fig 1.4B) [26].
One of the most important transcription factors for maintenance of endocrine βcells is MafA. MafA is first expressed at E13.5 in insulin+ cells, and persists into
postnatal and adult stages [27]. Ablation of MafA during embryogenesis does not have a
profound impact on β-cell specification, likely due to upregulation of the closely related
protein MafB (discussed later) [27]. However, MafA is directly responsible for the
transcriptional regulation of insulin and other glucose-responsive genes [27]. Ablation of
MafA in the mature β-cell results in loss of insulin biosynthesis and secretion (Fig 1.4B).
Furthermore, studies have demonstrated that MafA is a very accurate barometer of β-cell
activity status [27]. When internal glucose levels are too high, MafA expression is
reduced and eventually lost, indicating β-cell dysfunction and loss of glucose
homeostasis [27].
While the transcription factors described above are generally β-cell specific, there
are several other factors equally important to β-cells expressed in multiple cell types.
19

Specifically, Nkx2.2 is a transcription factor that is expressed in all endocrine cell types,
except δ-cells, starting around E9.5 [28]. Ablation of Nkx2.2 results in loss of β-, α-, and
PP-cells with a concomitant increase in ε-cells (Fig 1.4B) [29]. Interestingly, in Nkx2.2
null mice there is a population of immature β-cells that don’t express Glut2 or
glucokinase (mature β-cell markers), but do express other markers of β-cells, suggesting
Nkx2.2 is crucial for proper β-cell maturation [29].

20

MafB, Brn4, and Arx are α-Cell Specific Transcription Factors Necessary for
Correct Specification.
Similar to endocrine β-cells, transcription factors are also important in α-cell
specification and maintenance. For many years the endocrine α-cell has not garnered as
much attention as its neighbor, the β-cell. However, since the proposal of the bihormonal
theory of diabetes, a higher degree of attention has focused on understanding the α-cell
and transcription factors important in its specification and maintenance. Much is still
unknown about the α-cell, including a list of important transcription factors similar to the
list for β-cells. Currently, only three α-cell specific transcription factors necessary for
specification and maintenance have been identified: MafB, Brn4, and Arx.
MafB is first expressed at E10.5 in hormone-producing endocrine cells (both
insulin+ and glucagon+) [30]. It is expressed in both α- and β-cells during embryogenesis,
but is restricted to α-cells after postnatal day (P)14 [30]. Ablation of MafB during
embryogenesis results in α- and β-cell maturation defects [31]. In a mouse model of
MafB ablation the number of glucagon+ and insulin+ cells is drastically reduced, although
total endocrine mass is unchanged [31]. The authors demonstrate that while immature αand β-cells do exist, these cells cannot become physiologically functional (Fig 1.4B) [31].
MafB continues to be expressed in adult α-cells from P14 onward, but a role for MafB in
maintenance of α-cell fate has not yet been explored [30].
Another α-cell specific transcription factor is Brn4. Brn4 is exclusively expressed
in endocrine α-cells beginning at E10 [32]. Ablation of Brn4 in mouse models does not
21

display a pancreatic phenotype, likely due to compensation by other factors [32]. Further
studies have demonstrated that Brn4 binds to and regulates glucagon gene transcription in
the endocrine α-cell (Fig 1.4B) [33].
The last transcription factor important in α-cell specification is the aristalessrelated homeobox gene (Arx) [34]. Numerous studies have demonstrated that Arx is
necessary and sufficient for proper specification of the endocrine α-cell, upon which I
will expand further in the following section. Arx appears to be an attractive target for
future transdifferentiation studies exploring novel therapies for diabetic patients.
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Figure 1.4: Transcription Factors are Necessary for Proper Endocrine Specification
and Maintenance. (A): Schematic depicting how transcription factors narrow endocrine
fate through multiple developmental stages. Pdx1 expression defines pancreatic
progenitor fate while Ngn3 expression restricts fate to the endocrine lineage. Cell
specific transcription factors are expressed in Ngn3+ endocrine progenitors and define
fate for each endocrine cell lineage. Many factors continue to be expressed after birth
and play a role in maintenance of cell fate. (B): Table outlining transcription factors
important for endocrine specification and maintenance. Columns outline embryonic
expression profile (2nd column from left), adult/mature expression profile (2nd column
from right), and ablation phenotype (right most column).
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Arx is necessary and sufficient for endocrine α-cell specification.
Arx is a paired homeodomain-containing transcription factor located on the Xchromosome at Xp22.13 [35]. Arx contains a variety of previously classified domains
including an aristaless domain, an octapeptide domain, three nuclear localization
sequences (NLS), a central acidic domain, and four polyalanine tracts [36]. Although Arx
contains activation (aristaless) and repression (octapeptide and polyalanine tract 4)
domains, several studies have demonstrated it mainly acts through a repressive
mechanism (Fig 1.5A) [37]. Furthermore, Arx has been shown to co-localize with the
co-repressors Groucho/Tranducin-like enhancer 1 (Tle1) and C-terminal binding proteins
(CtBPs) [37,38]. This colocalization increases Arx’s repressive ability in in vitro assays
[37].
Previous studies have demonstrated that Arx is necessary and sufficient for α-cell
specification. Global ablation of Arx results in complete loss of glucagon-producing αcells with a concomitant increase in β- and δ-cells, maintaining normal pancreatic
endocrine mass [34]. Ablation of Arx in pancreatic or endocrine progenitors demonstrates
similar results, indicating this defect occurs in endocrine cell development (Fig 1.5B)
[39]. Arx is Ngn3-dependent, and is first expressed in Ngn3+ endocrine progenitors [34].
After specification, Arx becomes restricted to glucagon+ cells, where it is maintained into
postnatal life [34]. While it has been proposed that loss of Arx leads to respecification of
presumptive α-cells into β- and δ-cell fates, lineage tracing has not been performed to
validate this model. Arx is also sufficient to specify an α-cell fate. Forced misexpression
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of Arx in the developing pancreas or islets results in the conversion of β- and δ-cells into
an α- and PP-cell fate (Fig 1.5B) [40].
Contrary to pancreatic Arx ablation, loss of the β-cell transcription factor Pax4 in
the developing pancreas results in loss of β- and δ-cells and a concurrent increase in αand PP-cells (described above) [26]. Work examining the opposing roles of Arx and
Pax4 in endocrine specification has demonstrated that these two factors negatively
regulate each other through direct DNA binding and co-repression [34]. Loss of Arx
results in a significant upregulation of Pax4 while in Pax4 mutant mice the converse is
true [34]. These data suggests that Arx and Pax4 help control the proper specification of
α- and β-cells through a dual repression model.
The interaction of Arx with other endocrine transcription factors has also been
explored, including the interaction between Arx and Nkx2.2. Mastracci and colleagues
demonstrated that loss of both Arx and Nkx2.2 causes an increase in ε-and δ-cells at the
expense of α- and β-cell populations, which are completely lost in this model [41].
However, the increase in ε-cell number does not correspond to increased ghrelin
transcript levels [41]. Furthermore, double mutants harbored a ghrelin+/somatostatin+
endocrine population not observed in controls [41]. Finally, although ablation of Nkx2.2
alone results in a drastic decrease in the number of PP-cells, this cell population is
restored in the double mutant mice [41]. Together these data demonstrates that there is a
novel interaction between Arx and Nkx2.2 that helps regulate endocrine cell fate and
specification. Future studies examining the interaction between different transcription

26

factors will help expand and clarify this as well as other interactions necessary for
endocrine cell fate specification and maintenance.
Together these previous studies show that Arx is necessary and sufficient for
proper α-cell specification in the developing pancreas. While the role of Arx in
specification has been described, a possible role in cell fate maintenance has not yet been
examined. Previous studies examining the role of the DNA methyltransferase, Dnmt1, in
adult β-cell maintenance suggests that such a role could exist [42]. Loss of Dnmt1 results
in progressive loss of DNA methylation, derepression of Arx, and transdifferentiation of
β-cells into a glucagon+ α-cell fate [42]. These data suggest that similar to its role during
embryogenesis, Arx is required for maintenance of α-cell fate in the adult pancreas.
Studies examining the role of Arx after specification are essential to determine a
potential role for Arx in maintenance of endocrine α-cell fate. Additionally, these studies
will be helpful in examining the possibility of using mature endogenous α-cells in
transdifferentiation experiments for novel treatments for type I and II diabetes.
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Figure 1.5: Arx is a homeodomain-containing transcription factor necessary for the
correct development of multiple tissue types
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Figure 1.5: Arx is a homeodomain-containing transcription factor necessary for the
correct development of multiple cell types. (A): Diagram outlining the domain
structure of the Arx protein. Arx contains an octapeptide domain, three nulclear
localization sequences, four polyalanine tracts, an acidic domain, a homeodomain, and an
aristaless domain. (B): Table outlining the role of Arx in the development of multiple
tissue types. Columns depict organ, model utilized, and resulting phenotype (from left to
right).
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Arx plays diverse roles in the development of multiple tissues.
While the role of Arx in the developing endocrine pancreas has been described,
Arx is also expressed in a variety of other tissues including the digestive tract, skeletal
muscle, testis, and brain [43]. The role of Arx in these other tissues has also been
examined (Fig 1.5B). In the digestive tract, ablation of Arx results in loss or severe
reduction of several enteroendocrine cell populations including gastrin-, glucagon/GLP1-, CCK-, and secretin-producing cell populations with an increase in somatostatinexpressing cells [44]. The role of Arx in the muscle and testis has also been described.
During myogenesis (the development of muscle fibers) Arx acts as a positive regulator
through its association with Mef2C and MyoD [45]. In testis development, ablation of
Arx results in a drastic decrease in Leydig cell number due to defects in Leydig
progenitor cells (Fig 1.5B) [46].
Finally, the role of Arx in neuronal development has been extensively described.
Arx is first detected at the 3-somite stage [47]. After the 10-somite stage, it is confined to
an area in the anterior neural plate where it is expressed throughout the telencephalic
structures, including the ganglionic eminence, cerebral cortex, and hippocampus [48].
Arx null mice die within a day of birth and display severe neuronal defects [49].
Phenotypically, Arx null mice have smaller brains, olfactory bulbs, and testes [49].
There are multiple developmental problems that are responsible for the observed
phenotypes. Defects exist in tangential migration from the medial ganglionic eminence to
the cortex, in radial and tangential migration in the striatum, radial migration in the
cortex, cholinergic neuronal differentiation, and development of GABAergic interneurons
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[49]. These defects result in a thickened striatum, thinner cortical plate, lissencephaly,
and severe loss of inhibitory GABAergic interneurons [49]. When taken together, these
data demonstrates that Arx plays multiple roles in neuronal development, including
patterning, proliferation, migration, differentiation, and axonal outgrowth and
connectivity (Fig 1.5B) [47].
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Mutation of Arx results in a spectrum of human mental disorders.
Similar to mouse models, mutation of ARX in human patients results in several
neurological disorders [50]. X-linked mental retardation (XLMR) is a heterogeneous
group of disorders that result from mutations in genes located on the X-chromosome [50].
XLMR dominantly affects male patients with some clinical defects reported for
heterozygous females [50]. Mutations in ARX contribute significantly to this group of
disorders. ARX mutations and the associated clinical disorders can be placed on a
spectrum, where more severe mutations result in more severe clinical outcomes and vice
versa [50]. This spectrum demonstrates a striking and unique genotype-phenotype
correlation, suggesting that ARX is directly responsible for the clinical presentations of
these patients [50].
The most severe ARX-related disorder, X-linked lissencephaly associated with
abnormal genitalia (XLAG), is associated with null and missense mutations of ARX [47].
XLAG patients present with lissencephaly, agenesis of the corpus callosum, neonatalonset intractable epilepsy, severe hypotonia, ambiguous genitalia, and death within the
first few months of life [51]. The clinical presentation of XLAG patients closely mirrors
that of Arx null mice, potentially allowing scientists to use Arx mouse models to develop
treatments for patients affected by ARX-related disorders [52].
While XLAG mutations are on the most severe end of the ARX-disorder
spectrum, the most common mutation is expansion of the first two polyalanine tracts of
ARX [53]. Expansion of the first polyalanine tract by an additional seven alanines is
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associated with the clinical disorder West syndrome, or infantile spasms (ISSX) [54].
Patients suffering from West syndrome present with infantile spasms, hypsarrythmia, and
mental retardation; however, they do not usually have brain malformations
(lissencephaly), and also have a longer life expectancy than XLAG patients [54].
To explore the mechanism behind the distinct differences in phenotype between
XLAG-like mutations of ARX and the polyalanine expansion of ARX found in West
syndrome, mice with a West syndrome expansion mutation were created [55,56]. Mice
with an expansion mutation of Arx are born in normal Mendalian ratios and have brains
that appear normal in size and gross morphology, unlike Arx null mice [55,56].
However, mutant mice do have seizures, and die within six months of birth [55].
Interestingly, GABAergic progenitor radial migration, which is absent in Arx null mice,
appears normal in Arx expanded mice [55]. In contrast, tangential migration is lost,
similar to the phenotype reported in the Arx null model [55]. Mechanistic studies behind
these phenotypes demonstrate selective derepression of a subset of Arx targets in the
polyalanine expansion mutant [57]. The authors attribute this selective derepression to
loss of proper association with a subset of co-repressors [57]. Specifically, an expanded
Arx demonstrated reduced, but not absent, association with Tle1 [57]. These studies
demonstrate that expansion of Arx results in context specific defects due to selective loss
of association with co-repressors.
Recently Itoh and colleagues explored the pancreatic phenotype in an ARX-null
XLAG patient [58]. Interestingly, they demonstrated that similar to Arx null mice,
human patients with null mutations in ARX have a complete loss of endocrine α-cells
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[58]. This study demonstrates that, similar to neuronal studies, Arx null mice and XLAG
patients display surprisingly similar pancreatic phenotypes. However, the question of
whether, similar to the brain, there is a genotype-phenotype correlation associated with
ARX/Arx mutation severity and the specification and maintenance of endocrine α-cells
remains unanswered. Future studies using non-null Arx mutations are necessary to study
this potential correlation. Furthermore, any impacts observed might lead to treatments
for Arx-related disorders, as well as type I and II diabetes mellitus.
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Summary and Specific Aims
Understanding endocrine α-cell specification and maintenance is essential to
provide knowledge in designing novel treatments type I and II diabetes. The
homeodomain-containing transcription factor, Arx, has been shown to be necessary and
sufficient for α-cell fate specification [34,40]. However, Arx continues to be expressed
in the mature α-cells and therefore could play an additional role in α-cell maintenance
throughout life[34].
Additionally, neuronal studies on the role of Arx in proper migration and
development of interneurons, and the human pathologies associated with different forms
of ARX mutations, have demonstrated a unique genotype-phenotype correlation [47].
Arx null mice and XLAG patients demonstrate strikingly similar pancreatic phenotypes,
namely a complete loss of endocrine α-cells [58]. Exploration of non-null Arx mutations,
and the resulting impact on endocrine α-cells, will provide further information on proper
endocrine specification and maintenance as well as whether a genotype-phenotype
severity correlation exists in the pancreas as it does in the brain.
The following chapters in my thesis aim to expand the knowledge of the role of
Arx in the endocrine α-cell. The goal of these experiments is to (1) determine the role
of Arx in maintenance of mature α-cell fate and (2) describe the effect a non-null
Arx mutation has on α-cell specification and maintenance. These results will
demonstrate the role of Arx in maintenance of α-cell fate, as well as provide a better
understanding of how a non-null Arx mutation impact α-cell development.
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CHAPTER II:
The Role of Arx in the Maintenance of Islet α-Cell Fate
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Abstract
The specification and differentiation of pancreatic endocrine cell populations (α-, β-, δ,
PP- and ε-cells) is orchestrated by a combination of transcriptional regulators. In the
pancreas, Aristaless-related homeobox gene (Arx) is expressed first in the endocrine
progenitors and then restricted to glucagon-producing α-cells. While the functional
requirement of Arx in early α-cell specification has been investigated, its role in
maintaining α-cell identity has yet to be explored. To study this later role of Arx, we have
generated mice in which the Arx gene has been ablated specifically in glucagonproducing α-cells. Lineage-tracing studies and immunostaining analysis for endocrine
hormones demonstrate that ablation of Arx in neonatal α-cells results in an α-to-β-like
conversion through an intermediate bihormonal state. Furthermore, these Arx-deficient
converted cells express β-cell markers including Pdx1, MafA, and Glut2. Surprisingly,
short-term ablation of Arx in adult mice does not result in a similar α-to-β-like
conversion. Taken together, these findings reveal a potential temporal requirement for
Arx in maintaining α-cell identity.
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Introduction
During development, the pancreas organizes into two distinct compartments:
the exocrine acinar cells, which secrete digestive enzymes, and the hormone producing
endocrine cells organized into islets of Langerhans [1]. These islets contain a core of
insulin-producing β-cells with a surrounding mantle of α, δ, ε, and PP-cells, which
produce the hormones glucagon, somatostatin, ghrelin, and pancreatic polypeptide,
respectively [2]. Islet β- and α-cells are the two key endocrine cell populations involved
in maintaining glucose homeostasis [3]. Disruption of this homeostasis through β-cell
loss or dysfunction leads to diabetes mellitus, a common metabolic disorder manifested at
all ages.
Given the limited supply of functioning β-cells in diabetics, one potential
treatment avenue is cell-replacement therapy [4]. Considerable effort has been invested
in identifying alternative β-cell sources through either directed differentiation from
embryonic/induced pluripotent stem cells or reprogramming from other differentiated cell
types [5]. Due to the close lineage relationship between α- and β-cells, the
reprogramming potential of an α-cell to adopt a β-cell fate has been recently investigated
[3]. In one study, new β-cells were generated from glucagon-producing α-cells through a
glucagon+insulin+ bihormonal intermediate state after a near-total β-cell loss [6].
Moreover, an α-to-β-cell lineage conversion was observed when Pax4, a pro-β-cell
transcription factor, was expressed in pancreatic endocrine progenitors or α-cells [7].
Similarly, forced expression of Pdx1 in endocrine progenitors leads to an increase in βcells and a decrease in α-cell number [8]. Although the α-cell population is mostly postmitotic, these studies collectively illustrate that α-cell fate can be plastic and is able to be
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reprogrammed to adopt β-cell fate. However, the extent of this plasticity during different
stages of an animal’s life is currently unknown.
One transcription factor capable of altering plasticity in endocrine cells is the
Aristaless-related homeobox gene (Arx). In the mouse pancreas, Arx is expressed in a
subset of endocrine progenitors and then restricted to glucagon-producing α-cells where it
is expressed throughout the life of the animal [9,10]. When misexpressed in the
developing pancreas, Arx is sufficient to force endocrine progenitors or β-cells to adopt
an α-cell fate [11]. These results demonstrate that Arx is sufficient for β-to-α-cell
reprogramming during development.
Although much is known regarding factors necessary and sufficient for endocrine
development, the factors required to maintain the identity of mature α-cells during
different stages are less clear. Mice with Arx null mutations in the germ-line, pancreatic
progenitors, or endocrine progenitors all display a complete loss of α-cells with a
concurrent increase in β- and δ-cells in the pancreas [9,10,12]. Moreover, α-cell loss has
been reported in patients with null mutations in ARX [13]. However, none of the existing
mouse models are suitable for determining the function of Arx in maintaining (as opposed
to establishing) mature α-cell identity. Further, lineage-tracing experiments have not yet
been performed to determine if loss of Arx leads directly to an α-to-β-cell conversion.
Here we show that Arx is required for α-cell lineage maintenance in the neonatal
pancreas, but not in the adult pancreas. During the neonatal period, ablation of Arx
results in loss of glucagon expression and activation of insulin and β-cell markers
through an insulin+glucagon+ bihormonal intermediate. In contrast, short-term Arx
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ablation in the adult pancreas does not result in either a loss of glucagon expression or an
activation of β-cell marker expression. These data suggest that Arx may act in a stageand context-specific manner in maintaining α-cell identity and reveal potential
differential plasticity between fetal and adult α-cells. When taken together, these findings
have important implications for the potential use of α-cells for the purpose of β-cell
replacement therapy.
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Results
Arx removal in neonatal glucagon-producing cells.
Arx is expressed in endocrine progenitors, α-cell precursors, and mature
glucagon-producing cells of the pancreas [9,10]. To investigate its role in the neonatal αcell, we generated mice with Arx ablation in glucagon+ cells (ArxL/Y or ArxL/L;GlucagonCre; referred to as GKO hereon). First, a Rosa-YFP reporter was used to assess the Cremediated recombination efficiency in our GKO model. In P5 control mice (including
Arx+/Y ;Glucagon-Cre, Rosa-YFP and Arx L/+ or +/+; Glucagon-Cre;Rosa-YFP), Arx
expression was found in all glucagon+ cells; however, only 13% of glucagon+ cells coexpressed Arx and YFP (Fig. 2.1A, C; white bar in control). All male and female control
animals utilized in these experiments were phenotypically identical according to their
islet morphology and were compared to their sex-matched GKO animals. These
observations indicate a low Cre-mediated recombination rate, which is in agreement with
what others have previously reported using this Glucagon-Cre transgenic mouse [19]. In
GKO;Rosa-YFP mutant mice, Arx protein was removed in all glucagon+YFP+ cells,
which equated to about 12% of glucagon+ cells (Fig. 2.1B, C; grey bar in GKO). This
result suggests that YFP expression faithfully marks cells that have undergone Arx
ablation. The low Cre-mediated recombination frequency was also observed in P21
animals (Fig. 2.2 and data not shown). Real-time PCR analysis from P5 and P21 animals
further showed Arx mRNA levels were decreased by 20% and 50% in GKO animals,
respectively, although not significantly (Fig. 1D). In addition, in P5 control animals,
while 90% of YFP+ cells co-expressed glucagon, approximately 10% of the YFP+ cells
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were positive for insulin staining due to some leakiness of the Cre (see bbelow
elow and data
not shown).

Figure 2.1: Arx is specifically ablated in YFP+ α-cells
cells of GKO;Rosa-YFP
GKO;Rosa
mice.
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Figure 2.1: Arx is specifically ablated in YFP+ α-cells of GKO;Rosa-YFP mice. P5
pancreatic sections were stained for glucagon (blue), Arx (red), and YFP (green). (A):
Arx is expressed in all glucagon+ cells in control;Rosa-YFP pancreata. A subset of
glucagon+Arx+ cells is YFP+. (B): In GKO;Rosa-YFP animals, there is a subset of
glucagon+ cells that express YFP. These YFP+ cells have lost Arx expression. Scale bar
represents 25µm. (C): Quantitative analysis of Arx and YFP expressing cells within
glucagon+ population in P5 animals. Over 500 total glucagon+ cells were counted with
three mice per group used. Error bars represent standard error of the mean with p-value
indicated. N.S: not significant. (D): Quantitative PCR analysis for Arx mRNA in total
pancreata at P5 and islets from P21 control and GKO animals. Control mRNA level was
set at one fold ± standard error of the mean. Male and female control and GKO animals
(n≥3) were sex-matched for all analyses.
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Figure 2.2: Arx is specifically ablated in P21 α-cells by Glucagon-Cre
Cre with Arxdeficient cells expressed YFP

49

Figure 2.2: Arx is specifically ablated in P21 α-cells by Glucagon-Cre with Arxdeficient cells expressed YFP. Pancreata were stained for glucagon (blue), Arx (red),
and YFP (green). (A): Arx is expressed in all glucagon+ cells in control;Rosa-YFP
pancreata. (B): In GKO;Rosa-YFP animals, Arx is ablated in all YFP+ cells. Male and
female GKO mice (n≥3) were analyzed and compared to their sex-matched controls.
Scale bar represents 50µm.

50

Arx ablation in the GKO mice results in an emergence of glucagon+ insulin+ coexpressing cells.
To determine whether loss of Arx in the α-cells of GKO mice may have resulted
in a change of cell fate in a small subset of cells, we performed double immunostaining
for glucagon and other endocrine hormones. Given that only 12% of the glucagonproducing cells have lost Arx expression, we did not expect to observe any significant
changes in the number of glucagon cells or the localization of these cells in P5 GKO
mice. Indeed, immunostaining analyses confirmed this anticipated result (Fig. 2.3A-H).
Real-time PCR analysis also revealed no significant changes in the mRNA levels of
glucagon transcript between control and GKO mice (Fig. 2.3I). Although hormone cell
numbers were not significantly altered, close examination revealed a small population of
glucagon+insulin+ bihormonal cells in the pancreas of GKO mice (Fig. 2.3B). These
bihormonal cells were only found in the GKO mice. There was no overlap or significant
differences in the expression of glucagon with somatostatin or PP between P5 GKO and
control mice (Fig. 2.3C-F). Endocrine cells expressing glucagon and ghrelin have been
reported in the developing and neonatal pancreas [20,21,22]. The number and location of
these glucagon+ghrelin+ cells were comparable between P5 control and GKO mice (Fig.
2.3G-H). Real-time PCR analysis did not reveal any significant changes in hormone
expression between P5 control and GKO animals (Fig. 2.3I-L). Together, these data
indicate that loss of Arx in glucagon+ cells results in misexpression of the β-cell hormone
insulin in glucagon+ α-cells.
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To determine the fate of this bihormonal population we evaluated glucagon,
insulin, somatostatin, PP, and ghrelin expression in the pancreata of P21 control and
GKO mice by immunostaining. Again, there was no significant change in the cell mass
or distribution associated with these endocrine populations (Fig. 2.4A-B). Interestingly,
while a few glucagon+insulin+ cells could still be found in the P21 GKO mice, the
frequency of this bihormonal population was dramatically reduced by this age relative to
P5. Instead, many of the remaining bihormonal cells in P21 GKO mice have reduced
glucagon staining in cells readily expressing insulin (Fig. 2.4A-B). These cells are likely
in the later stage of their α-to-β-like cell fate conversion. These observations suggest that
upon ablation of Arx, insulin expression is activated in the glucagon-producing α-cell,
which then gradually loses glucagon expression. Finally, we evaluated mRNA levels for
β-cell (Pdx1 and Nkx6.1) and α-cell (MafB and Brn4) markers in the islets isolated from
P21 control and GKO mice. From the real-time PCR analysis, we observed a significant
upregulation of Pdx1 mRNA and an upward trend of Nkx6.1 levels (Fig. 2.4J).
Conversely, we detected a significant reduction in Brn4 with a small downward trend in
MafB expression (Fig. 2.4J). While the significant changes in the mRNA levels of Pdx1
and Brn4 data are surprising in the context of the small changes in hormone expression,
this result could be due to direct Arx regulation. Arx could potentially directly repress
Pdx1 and activate Brn4, which would result in a drastic increase of Pdx1 (and resulting
decrease of Brn4) upon Arx ablation. When taken together, these data suggest that
glucagon-producing cells require Arx to maintain α-cell identity and repress β-cell
markers during neonatal life.
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Figure 2.3: Loss of Arx in glucagon+ cells results in the appearance of a
glucagon+insulin+ population.
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Figure 2.3: Loss of Arx in glucagon+ cells results in the appearance of a
glucagon+insulin+ population. (A-H): P5 control and GKO pancreata were stained for
glucagon (green), insulin (red; A, B), somatostatin (Sst; red; C, D), PP (red; E, F), and
Ghrelin (red; G, H). Glucagon+insulin+ cells are the only bihormonal population unique
to GKO animals (B, D, F). Glucagon/ghrelin coexpressing cells are both found in control
and GKO animals (G, H). Male and female control and GKO animals (n≥3) were sexmatched for all analyses. Scale bar denotes 25µm. (I-L): Quantitative PCR analysis
examining glucagon (I), insulin (J), somatostatin (K), and PP (L) gene expression in P5
control and GKO animals. Control mRNA level was set at one fold ± standard error of
the mean. For all GKO and control groups, at least 3 biologic replicates were performed.
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Figure 2.4: Loss of glucagon+insulin+ cells in P21 GKO animals.
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Figure 2.4: Loss of glucagon+insulin+ cells in P21 GKO animals. (A-H):
Immunostaining for glucagon (A-H), insulin (A-B), somatostatin (C-D), PP (E-F), and
ghrelin (G-H) in P21 control and GKO animals with merged images shown. Glucagon
positive cells do not overlap with insulin (A, B), somatostatin, (C, D) or PP (E, F).
Ghrelin is no longer expressed at P21 (G, H). (I): Total insulin, glucagon, somatostatin,
and PP cell mass in the pancreata of P21 control and GKO mice. Male and female GKO
mice (n≥3) were analyzed and compared to their sex-matched controls. Scale bar denotes
25µm. (J): Quantitative PCR analysis for P21 control and GKO islets for β-cell markers
Pdx1 and Nkx6.1 and α-cell markers MafB and Brn4. “*” denotes p<0.05. Error bars
represents standard error of the mean.
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Arx-deficient cells fail to maintain α-cell identity
To directly determine the origin of the glucagon+insulin+ cells seen in P5 GKO
mice, lineage-tracing studies were performed in P5 GKO mice. Triple-immunostaining
for glucagon, insulin, and YFP were performed in the pancreas of control;Rosa-YFP and
GKO;Rosa-YFP mice. YFP expression was detected in only a subset of glucagonproducing cells at P5 (Fig. 2.5A-B), due to the low frequency of the Cre-mediated
recombination in the Glucagon-Cre transgenic mice (Fig. 2.1). The majority of YFP+
cells in the P5 control mice expressed glucagon (Fig. 2.5A, E and F) though a very small
number of insulin-producing cells positive for YFP expression were found (blue),
demonstrating relatively high, though not 100%, fidelity of the Cre-mediated
recombination (Fig. 2.5E and F). In P5 GKO mice, we noticed an emergence of
glucagon+insulin+YFP+ (purple) cells and an increase in the number of insulin+YFP+
(blue) cells while the number of glucagon+YFP+ (red) cells was reduced compared to
controls (Fig. 2.5A-B, E and F).
To follow up with our previous observations that the glucagon+insulin+ cell
number has dramatically reduced by P21, we evaluated the pancreata of control;RosaYFP and GKO;Rosa-YFP mice at P21 for glucagon, insulin, and YFP expression.
Interestingly, corresponding to the previously described disappearance of bihormonal
cells by P21 (Fig. 2.4A-B), the majority of YFP+ cells in GKO;Rosa-YFP pancreata at
this stage were insulin+ (blue) with only a small percentage of YFP+ cells expressing both
insulin and glucagon (purple) or glucagon alone (red) (Fig. 2.5C-D and G). These data
demonstrate that Arx loss in glucagon-producing α-cells leads to a failure in maintaining
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α-cell identity and a conversion to a β-cell-like fate. Taken together, these lineage-tracing
data indicate that the loss of neonatal Arx in glucagon-producing cells results in a cell fate
conversion from a glucagon+ α-cell into an insulin+ β-cell-like fate through a bihormonal
intermediate.
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Figure 2.5: Lineage tracing studies demonstrate that Arx ablated α-cells become
glucagon+insulin+ at P5 then insulin expressing at P21.
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Figure 2.5: Lineage tracing studies demonstrate that Arx ablated α-cells become
glucagon+insulin+ at P5 then insulin expressing at P21. (A-D): Triple immunostaining
for glucagon (red), insulin (blue), and YFP (green) in control;Rosa-YFP and GKO;RosaYFP pancreata at P5 and P21. YFP+ cells in P5 or P21 control;Rosa-YFP animals are
positive for glucagon (A and C;). “*” denote insulin cells that are negative for glucagon
or YFP expression (A and C; *) Glucagon+insulin+YFP+ cells are found in P5 GKO
animals (B; ), but rarely in controls (A). YFP+ cells are positive for glucagon in control
P21 pancreata (C; ) but insulin+ in P21 GKO pancreata (D; ). (E): Schematic outlining
cell populations resulting from lineage-tracing and immunostaining analysis. (F, G):
Quantification of hormone expression in YFP+ cells at P5 (F) and P21 (G). At P5 and
P21, over a total of 10,000 cells were counted from 3-5 animals per group. Out of the
10,000 cells counted, approximately 1,000 cells were YFP+. Each category was
calculated and presented as a percentage of total YFP+ cells per animal and then
averaged. Error bars are denoted as standard error of the mean with significance (p≤0.05)
between each color denoted with “*”, “”, and “”. Male and female GKO mice (n≥3)
were used for all analysis and compared to their sex-matched controls. Scale bar
represents 25µm.

61

Markers associated with mature β-cells are activated in Arx-deficient YFP+ cells.
To further examine how closely these newly converted β-like-cells were to true β-cells,
expression of several known β-cell markers including Glut2, MafA, and Pdx1 were
examined in control;Rosa-YFP and GKO;Rosa-YFP mice at P5 and P21. In P5
GKO;Rosa-YFP animals, there was a significant increase in the number of YFP+ cells
coexpressing Glut2, MafA, or Pdx1 (Fig. 2.6B, D, F, G, I, K). Similar increases were
also seen in P21 mice with a further increase in the number of YFP+ cells expressing
Glut2 and Pdx1 in the pancreata of the GKO;Rosa-YFP mice (Fig. 2.6H, J, L, Fig. S3).
As expected, due to the leakiness of the Glucagon-Cre transgene, we did find a small, but
not significant, percentage of YFP+ cells that coexpressed Glut2, MafA, or Pdx1 in P5 or
P21 control;Rosa-YFP mice (Fig. 2.6A, C, E, G, I, K). Taken together, these data
demonstrate that a subset of the converted cells in the GKO;Rosa-YFP mice activate βcell markers as well as insulin expression in the absence of Arx.
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Figure 2.6: YFP+ cells in GKO animals express markers of mature β-cells at P5 and
P21.
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Figure 2.6: YFP+ cells in GKO animals express markers of mature β-cells at P5 and
P21. (A-F): Control;Rosa-YFP and GKO;Rosa-YFP P5 pancreata were stained for
insulin (blue), YFP (green), Glut2 (A,B,red), MafA (C,D,red), Pdx1 (E,F,brown). YFP+
cells in GKO animals are insulin+Glut2+ (B; ), insulin+MafA+ (D; ) and insulin+Pdx1+
(F; ). In control animals, the majority of YFP+ do not express β-cell markers (A,C,E).
The YFP+ cells seen in exocrine tissue (panels E and F) is background due to the
combined IHC, IF staining method used and not true signal. (G-L): Quantification of
percentage of YFP+ cells that express or do not express Glut2 at P5 (G) and P21 (H),
MafA at P5 (I) and P21 (J), and Pdx1 at P5 (K) and P21 (L). Over 200 YFP+ cells were
counted for each stage with 3-5 animals per group. Error bars represent standard error of
the mean with significance between each cell population (p≤0.05) denoted as “*” and
“”. Male and female GKO mice (n≥3) were used for all analysis and compared to their
sex-matched controls. Scale bar represents 25µm.
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Short-term ablation of Arx in adult α-cells does not lead to loss of α-cell identity.
To explore the requirement for Arx in the maintenance of adult α-cell fate, we
used a global, tamoxifen-inducible transgenic mouse model to ablate Arx in adult
animals. Two-month-old control and ArxL/Y;pCAGG-CreER (IKO) mice were injected
with tamoxifen for three consecutive days and the animals sacrificed two weeks later for
tissue analysis (Fig. 2.7A). Efficiency of Arx removal was evaluated by immunostaining
in control and IKO mice. While Arx expression was found in glucagon+ cells in control
animals, all glucagon cells in IKO animals have lost Arx expression (Fig. 2.7B, B’, C, C’;
marked by arrows). To determine the impact of short-term Arx ablation in adult α-cells,
gene expression and immunostaining for endocrine hormones were examined in control
and IKO animals (Fig. 2.7D-I). Real-time PCR analysis revealed no significant changes
in the mRNA levels of hormone genes between control and IKO islets (Fig. 2.7K). We
also did not detect any significant changes in the numbers of glucagon-, insulin-,
somatostatin-, and PP-producing cells in the IKO mice compared to controls (Fig. 2.7DJ). Unlike P5 GKO mice in which a large proportion of Arx-glucagon+insulin+ cells were
found (Fig. 2.7A-B), we detected only a small number of bihormonal cells in adult IKO
mice, which were not proportionally significant (less than 0.1%; data not shown).
Additionally, analysis of α- and β-cell factors including MafB, Brn4, Glut2, and Pdx1
also did not reveal any significant changes in transcriptional profile of IKO animals (Fig.
2.7L). Since the pCAGG-Cre is globally expressed, the IKO animals develop an
intestinal phenotype that excludes any meaningful analysis to explore the long-term
impact of Arx on adult α-cell (data not shown). Taken together, using our current mouse
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model with short-term Arx ablation, these findings demonstrate that Arx is likely
dispensable in maintaining α-cell identity in adult mice. Future experiments utilizing an
inducible α-cell specific Cre transgenic mouse will be required to study the long-term
requirement for Arx in the maintenance of α-cell fate.
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Figure 2.7: Short-term complete ablation of Arx in adult mice does not result in a
loss of α-cells or changes in endocrine cell populations.
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Figure 2.7: Short-term complete ablation of Arx in adult mice does not result in a
loss of α-cells or changes in endocrine cell populations. (A): Diagram outlining
experimental design. (B-C): Arx (red) is expressed in glucagon (green) cells in control
(B,B’; arrows) but lost in IKO (C,C’;arrows) animals. Asterisks (*) mark autoflourescent
blood cells and are non-specific staining. (D-I): Control and IKO pancreata were stained
for glucagon (green), insulin (red; D,E), somatostatin (Sst; red; F,G), and PP (red; H,I).
No significant colocalization of glucagon with other hormones was seen in control or
IKO mice. Male control and IKO mice were used for analysis though female control and
IKO mice produced similar results. Scale bar denotes 75µm.
(J): Endocrine cell number quantification for insulin, glucagon, somatostatin, and PP in
control and IKO animals (over 10,000 cells were counted from 3 animals per group). (KL): Quantitative PCR analysis of gene expression in control and IKO islets. Results are
displayed as fold change relative to control with error bars representing the standard error
of the mean. For all analysis n=3.
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Discussion
This study demonstrates a requirement of Arx in α-cell fate maintenance.
Ablation of Arx in neonatal glucagon+ cells results in a loss of α-cell identity and
conversion into an insulin-producing β-cell-like fate (Fig. 2.8). Conversely, short-term
ablation of Arx in adult animals did not result in a significant loss or conversion of α-cells
or an increase in β-cells or β-cell markers (Fig. 2.8). Our findings from neonates and
adults expand the previously defined role of Arx in the specification of α-cells. When
taken together, Arx plays a role during specification as well as during early maintenance
of α-cell fate, but appears not to be required in adult animals for its fate maintenance.
Others have shown that ablation of Arx at any stage of specification results in a
complete loss of the α-cell lineage with a concomitant increase of β- and δ-cells
[9,10,12,23]. As there is no change in total endocrine mass reported in these studies,
these α-cells likely undergo re-specification into β- and δ-cell lineages. Our findings add
significant support to these observations by using lineage tracing to directly demonstrate
that Arx-ablated α-cells convert to β-like cells in neonatal animals. Interestingly, our
data, while showing coexpression of glucagon and insulin, does not show coexpression of
glucagon and somatostatin. Our initial hypothesis was that Arx-deficient α-cells would
give rise to both somatostatin and insulin populations. It is possible that the inefficiency
of the Glucagon-Cre did not enable us to detect a rare population of
glucagon+somatostatin+ cells. Alternatively, as the animal ages, the plasticity of cells
among different endocrine fates could be altered.
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Previous studies have demonstrated that endocrine cell fate is relatively
undifferentiated during gestation such that ablation of single transcription factors results
in loss of cell fate [2]. As endocrine cells mature, however, this plasticity drastically
decreases, and more extreme measures are needed to convert one endocrine cell type to
another [4,6,8]. While Pdx1 is normally restricted to β-cells, early overexpression in αcells results in a postnatal loss of glucagon-expressing α-cells with a concomitant gain of
insulin-producing β-cells demonstrating an α-to-β-cell fate conversion [8]. Conversely,
overexpression of Pdx1 in adult α-cells does not result in a similar conversion; instead,
these cells maintain proper cell identity [8]. The potential temporal requirement of Arx
closely parallels the results obtained through Pdx1 overexpression in α-cells. Early in
development, endocrine cell fate appears more plastic and subject to reprogramming.
During later life, however, cell fate is more defined, and as a result, reprogramming is
more difficult to achieve.
Interestingly, although overexpression of Pdx1 in α-cells results in a gain of
insulin-producing cells, those cells did not appear to lose all markers of α-cell fate [8].
Examination of immunostaining for the expression of β-cell-specific factors in the Arx
ablated neonatal animals demonstrates that YFP+ cells are at least partially reprogrammed
with the expression of Glut2, MafA, and Pdx1. While Arx is necessary to maintain α-cell
fate during development, loss of Arx, even immediately after specification, may not be
sufficient to fully reprogram cells into a functional β-cell fate. Due to the low efficiency
of the Cre utilized in our study, functional analysis of the insulin-producing cells derived
from Arx ablation in α-cells was not feasible.
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As the animal ages, there could be epigenetic changes that have occurred during
the process of specification or maturation that inhibit these Arx deficient cells from
becoming functional β-cells under homeostatic conditions. In fact, epigenetic
modification has been shown to play important roles in the differentiation and
maintenance of cell types. A recent study demonstrates that α-to-β-cell reprogramming
could be promoted by manipulating the histone methylation signature in mammalian
pancreatic islets [24]. Conditions of stress, however, may also make cell fate transitions
more fluid. It has been shown that excessive loss of β-cell mass, induced by
administration of a β-cell specific toxin, results in spontaneous reprogramming of α-cells
into a β-cell fate [6]. Additionally, partial pancreatectomy in mice and rats can result in
regeneration of β-cells through the conversion of duct cells or duct progenitor cells
[25,26]. These studies demonstrate that while cell fate is more defined in adult animals,
extreme conditions can force a non-β-cell into a β-cell fate. Future studies examining this
possibility should be performed and will elucidate limits to cell fate maintenance in adult
animals and how to overcome those limits. Particularly, the ability to utilize α-cells for
conversion to functional β-cells could be a potential therapy for diabetes.
Finally, it is important to note that our current adult IKO mouse model does not
allow for a complete investigation for the role of Arx in adult α-cells. Arx is required in
early enteroendocrine cell development of the digestive tract [27]. Therefore mice with
Arx removal in the intestine have alterations of specific enteroendocrine cell population,
which lead to lipid malabsorption and diarrhea ([27]; and unpublished observations).
Since the adult IKO mouse model was generated using a global inducible Cre transgenic
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mouse, enteroendocrine cell populations were impacted (unpublished observations). It is
important to note that we did notice a 0.1% increase in the number of bihormonal cells in
IKO mice (data not shown). However, whether this small change is due to the direct
impact upon Arx loss in α-cells or changes in the animal’s physiology remains to be
determined. An α-cell specific inducible Arx-deficient mouse model combined with
lineage tracing studies will be required to precisely determine the role of Arx in adult αcells.
In conclusion, the current study demonstrates a potential temporal requirement for
Arx in maintenance of α-cell fate. Ablation of Arx in neonatal α-cells results in a loss of
glucagon expression and a conversion of this cell population to adopt an insulinproducing β-cell-like fate. However, short-term loss of Arx in adult animals does not
phenocopy this result but instead suggests that Arx is dispensable in maintaining α-cell
fate in adulthood. These data expand the knowledge of the field not only related to the
role of Arx in the endocrine α-cell but also in regards to global temporal restrictions for
reprogramming endocrine cells. Future studies examining this temporal requirement, as
well as perturbations to the cell that circumvent these restrictions, will help clarify this
plasticity and bring understanding to endocrine cell fate specification, maintenance, and
therapeutic potential.
Note: The data presented in this chapter has been published in PLOS ONE as an Original
Research Article entitled,
Pancreatic α-cell specific deletion of mouse Arx leads to α-cell identity loss.
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Figure 2.8: Proposed model showing that Arx is necessary to maintain α-cell fate in
neonatal islets but not in mature α-cells in adult animals.
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Figure 2.8: Proposed model showing that Arx is necessary to maintain α-cell fate in
neonatal islets but not in mature α-cells in adult animals. Loss of neonatal Arx results
in the conversion of glucagon+ α-cells into an insulin-producing β-like-cell through a
bihormonal intermediate.
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Materials and Methods
Ethics Statement
The Children’s Hospital of Philadelphia’s Institutional Animal Care and Use Committee
(IACUC) approved all animal experiments under the protocol number 2011-10-756.
CLM monitored all animal studies.
Animals and Breeding Strategy
The derivation of the ArxL/Y and Glucagon-Cre transgenic lines has previously been
described [14,15,16]. To generate ArxL/Y;Glucagon-Cre mice, ArxL/+;Glucagon-Cre and
ArxL/Y mice were mated on a BL6 background. Male and female ArxL/Y or
ArxL/L;Glucagon-Cre mice were phenotypically indistinguishable in terms of their islet
morphology, size, body size and weight. All mutants used in our analysis were compared
to their sex-matched controls. Arx+/Y;Glucagon-Cre, Arx+/Y, ArxL/+ and ArxL/+;GlucagonCre mice were used for controls with no observable phenotypic differences in the islets
between any of them. The reporter Rosa26YFP/YFP was mated into this line in either
heterozygosity or homozygosity for lineage tracing studies, which yielded the same result
in all experiments [17]. The generation of pCAGG-CreER animals has been previously
described [18]. ArxL/Y or ArxL/L;pCAGG-CreER animals were generated by crossing
ArxL/+;pCAGG-CreER females to ArxL/Y males. Male and female mutants were
phenotypically indistinguishable in the endocrine pancreas and both were used in this
study.
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Immunohistochemistry and Histology
All dissections were performed in cold 1X PBS and tail or toe snips collected for
genotyping. Tissues were fixed in cold 4% paraformaldehyde overnight at 4°C,
embedded in paraffin, and 8µm sections collected. Antigen retrieval was performed in
10mmol citric acid buffer (pH 6.0) and endogenous peroxidase, avidin D, and biotin
activity blocked with 3% H2O2 (Sigma) and Avidin/Biotin Blocking Kit (Vector),
respectively. Endogenous protein was blocked with CAS-Block reagent (Invitrogen).
Slides were incubated in primary antibody overnight at 4°C. Primary antibodies used
were: Insulin (MS 1:400, Thermo Scientific and GP 1:1000, Abcam), Glucagon (1:3000,
Millipore), Somatostatin (1:200, Invitrogen), PP (1:200, Invitrogen), Arx (1:250, gift
from Dr. Kanako Miyabayashi at Kyushu University), GFP (1:250, Abcam), Ghrelin
(1:200, Santa Cruz), Pdx1 (1:200, Santa Cruz), MafA (1:1000, Bethyl), Glut2 (1:1000,
Millipore), and Chromogranin A (1:3000, DiaSornin). After rinsing in PBS, appropriate
secondary antibodies were added for two hours at room temperature.
Immunohistochemical detection was performed with the VECTASTAIN ABC kit
(Vector Laboratories) and diaminobenzidine tetrahydrochloride (DAB) as the substrate.
Immunofluorescence utilized secondary antibodies conjugated to Cy3, Cy2 or Cy5. All
images were obtained using a Leica DM6000B microscope.
Real-Time PCR Analysis
Total RNA was extracted in TRIZOL (Invitrogen) using the protocol provided with
reagent. Oligo-dT, Superscript II, and additional required reagents were used to
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synthesize cDNA (Invitrogen). PCR reactions were performed using Brilliant SYBR
Green PCR Master Mix (Agilent) in the Stratagene Mx3005P real-time PCR machine.
All PCR reactions were performed in duplicate for each sample with at least 3 animals
per group analyzed with reference dye normalization. Primer sequences are available
upon request.
Hormone Cell Quantification
Hormone-positive cells from pancreatic sections were counted, averaged, and normalized
to either total pancreatic area or total endocrine cell number. Three separate regions of
each pancreas were used for quantification in both control and mutant mice. At least three
animals for each group were used for quantification in all analyses. To determine
hormone cell mass, hormone-positive area as well as pancreatic area was measured using
the Aperio Image Analysis System. These areas as well as weight of the pancreas was
used to determine hormone cell mass. For specific hormone cell number, hormone
positive cells were counted and normalized to total endocrine cell number, which was
determined by combining counts for all endocrine hormones (insulin, glucagon,
somatostatin, and PP). Over 10,000 total endocrine cells were counted for each analysis
consisting of over 5,000 insulin+, over 1,000 glucagon+ and somatostatin+, and over 500
PP+ cells.
Islet Isolation
For P21 and adult RNA analysis, islet isolation was performed by injecting 5 mL
Collagenase P (Roche) in HBSS with 0.02% BSA (Sigma) into the clamped pancreatic
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duct to inflate the pancreas. Once inflated and removed, pancreatic tissue was incubated
in 15mL CollagenaseP/HBSS at 37°C at 50rpm for 16 minutes to digest exocrine tissue.
After spin down and rinse, islets were isolated from remaining exocrine tissue in HBSS.
Upon isolation, islets were placed in TRIZOL for RNA extraction.
Tamoxifen Induction
Two-month-old male and female mice, matched with littermate controls, were injected
intraperitoneally (IP) with 50µg/g body weight of 10mg/ml tamoxifen (Sigma) solution,
which consisted of 10% ethanol and 90% sunflower seed oil (Sigma). Injections were
performed for three consecutive days followed by a two-week chase. After the chase
period, pancreatic tissue was removed and processed for either immunostaining or RNA
analysis.
Statistical Analysis
All values are presented as average ± standard error of the mean. Significance was
determined using a two-tailed Student’s t-test. p-values less than or equal to 0.05 were
considered significant.

79

References:
1. Jorgensen MC, Ahnfelt-Ronne J, Hald J, Madsen OD, Serup P, et al. (2007) An
illustrated review of early pancreas development in the mouse. Endocr Rev 28:
685-705.
2. Collombat P, Hecksher-Sorensen J, Serup P, Mansouri A (2006) Specifying pancreatic
endocrine cell fates. Mech Dev 123: 501-512.
3. Bramswig NC, Kaestner KH (2011) Transcriptional regulation of alpha-cell
differentiation. Diabetes Obes Metab 13 Suppl 1: 13-20.
4. Juhl K, Bonner-Weir S, Sharma A (2010) Regenerating pancreatic beta-cells: plasticity
of adult pancreatic cells and the feasibility of in-vivo neogenesis. Current opinion
in organ transplantation 15: 79-85.
5. Borowiak M, Melton DA (2009) How to make beta cells? Current opinion in cell
biology 21: 727-732.
6. Thorel F, Nepote V, Avril I, Kohno K, Desgraz R, et al. (2010) Conversion of adult
pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 464: 11491154.
7. Collombat P, Xu X, Ravassard P, Sosa-Pineda B, Dussaud S, et al. (2009) The ectopic
expression of Pax4 in the mouse pancreas converts progenitor cells into alpha and
subsequently beta cells. Cell 138: 449-462.
8. Yang YP, Thorel F, Boyer DF, Herrera PL, Wright CV (2011) Context-specific alphato-beta-cell reprogramming by forced Pdx1 expression. Genes Dev 25: 16801685.
9. Mastracci TL, Wilcox CL, Arnes L, Panea C, Golden JA, et al. (2011) Nkx2.2 and Arx
genetically interact to regulate pancreatic endocrine cell development and
endocrine hormone expression. Dev Biol.
10. Collombat P, Mansouri A, Hecksher-Sorensen J, Serup P, Krull J, et al. (2003)
Opposing actions of Arx and Pax4 in endocrine pancreas development. Genes
Dev 17: 2591-2603.
11. Collombat P, Hecksher-Sorensen J, Krull J, Berger J, Riedel D, et al. (2007)
Embryonic endocrine pancreas and mature beta cells acquire alpha and PP cell
phenotypes upon Arx misexpression. J Clin Invest 117: 961-970.
12. Hancock AS, Du A, Liu J, Miller M, May CL (2010) Glucagon deficiency reduces
hepatic glucose production and improves glucose tolerance in adult mice. Mol
Endocrinol 24: 1605-1614.

80

13. Itoh M, Takizawa Y, Hanai S, Okazaki S, Miyata R, et al. (2010) Partial loss of
pancreas endocrine and exocrine cells of human ARX-null mutation:
consideration of pancreas differentiation. Differentiation 80: 118-122.
14. Quoix N, Cheng-Xue R, Guiot Y, Herrera PL, Henquin JC, et al. (2007) The GluCreROSA26EYFP mouse: a new model for easy identification of living pancreatic
alpha-cells. FEBS letters 581: 4235-4240.
15. Fulp CT, Cho G, Marsh ED, Nasrallah IM, Labosky PA, et al. (2008) Identification of
Arx transcriptional targets in the developing basal forebrain. Hum Mol Genet 17:
3740-3760.
16. Herrera PL (2000) Adult insulin- and glucagon-producing cells differentiate from two
independent cell lineages. Development 127: 2317-2322.
17. Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, et al. (2001) Cre reporter
strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus.
BMC developmental biology 1: 4.
18. Hayashi S, McMahon AP (2002) Efficient recombination in diverse tissues by a
tamoxifen-inducible form of Cre: a tool for temporally regulated gene
activation/inactivation in the mouse. Dev Biol 244: 305-318.
19. Lu J, Herrera PL, Carreira C, Bonnavion R, Seigne C, et al. (2010) Alpha cellspecific Men1 ablation triggers the transdifferentiation of glucagon-expressing
cells and insulinoma development. Gastroenterology 138: 1954-1965.
20. Chao CS, Loomis ZL, Lee JE, Sussel L (2007) Genetic identification of a novel
NeuroD1 function in the early differentiation of islet alpha, PP and epsilon cells.
Dev Biol 312: 523-532.
21. Prado CL, Pugh-Bernard AE, Elghazi L, Sosa-Pineda B, Sussel L (2004) Ghrelin
cells replace insulin-producing beta cells in two mouse models of pancreas
development. Proc Natl Acad Sci U S A 101: 2924-2929.
22. Sussel L, Kalamaras J, Hartigan-O'Connor DJ, Meneses JJ, Pedersen RA, et al.
(1998) Mice lacking the homeodomain transcription factor Nkx2.2 have diabetes
due to arrested differentiation of pancreatic beta cells. Development 125: 22132221.
23. Collombat P, Hecksher-Sorensen J, Broccoli V, Krull J, Ponte I, et al. (2005) The
simultaneous loss of Arx and Pax4 genes promotes a somatostatin-producing cell
fate specification at the expense of the alpha- and beta-cell lineages in the mouse
endocrine pancreas. Development 132: 2969-2980.
24. Bramswig NC, Everett LJ, Schug J, Dorrell C, Liu C, et al. (2013) Epigenomic
plasticity enables human pancreatic alpha to beta cell reprogramming. The
Journal of clinical investigation 123: 1275-1284.
81

25. Lee SH, Hao E, Levine F (2011) beta-Cell replication and islet neogenesis following
partial pancreatectomy. Islets 3: 188-195.
26. Li WC, Rukstalis JM, Nishimura W, Tchipashvili V, Habener JF, et al. (2010)
Activation of pancreatic-duct-derived progenitor cells during pancreas
regeneration in adult rats. Journal of cell science 123: 2792-2802.
27. Du A, McCracken KW, Walp ER, Terry NA, Klein TJ, et al. (2012) Arx is required
for normal enteroendocrine cell development in mice and humans. Developmental
biology 365: 175-188.

82

Chapter III:

The Role of Arx in Maintenance of Adult α-cell Fate
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Abstract
Type II diabetes is a global health crisis, affecting more than 25 million people in
the United States alone. Diabetes is a metabolic disorder that stems from unregulated
glucose homeostasis, which is normally maintained by glucagon-producing α-cells and
insulin-producing β-cells in the endocrine pancreas. In order to develop novel treatments
for type II diabetes, knowledge of normal endocrine cell development and maintenance is
essential. Previous studies have demonstrated the importance of transcription factors in
endocrine cell development.
An important transcription factor for endocrine α-cells is the aristaless-related
homeobox gene (Arx). Previous studies have demonstrated that Arx is necessary for
proper specification and maintenance of α-cell fate in the neonatal pancreas, but is
dispensable for short-term α-cell fate maintenance in adult animals. However, the longterm impact of Arx ablation in mature α-cells has not been studied.
Here, we show that upon long-term ablation of Arx in mature α-cells, mice
become more glucose tolerant and lose weight gradually over time. Phenotypic analysis
demonstrated normal glucagon+ numbers; however, a majority of α-cells co-express
insulin or PP. Finally, in vitro secretion assays demonstrate loss of glucagon secretion
and content. Instead, Arx-ablated islets secrete insulin in response to both α and β
stimuli. When taken together, these data demonstrate that long-term ablation of Arx in
the mature α-cell results in loss of cell fate maintenance and conversion into an α-β-PP
hybrid cell.
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Introduction:

Type II diabetes is a metabolic disorder that affects over 25 million people in the
United States [1]. The hallmarks of type II diabetes are inadequate insulin secretion
combined with excess glucagon due to loss of proper glucose homeostasis [2]. Glucose
homeostasis is largely maintained by the endocrine pancreas, which secretes insulin and
glucagon in response to elevated and reduced blood glucose levels, respectively [3].
Thus, novel therapies to treat type II diabetes focus on the endocrine pancreas and seek to
restore blood glucose homeostasis [4].
The pancreas is a two-component organ situated between the stomach and
duodenum of the digestive tract [5]. The pancreas is comprised of an exocrine portion,
which secretes digestive enzymes, and an endocrine component, which produces and
secretes hormones involved in glucose homeostasis and metabolism [5]. The murine
endocrine portion of the pancreas is organized into Islets of Langerhans, consisting of a
core of insulin-producing β-cells with a surrounding mantle of α-, δ-, PP-, and ε-cells,
which secrete the hormones glucagon, somatostatin, Pancreatic Polypeptide (PP), and
ghrelin, respectively [5].
Glucose homeostasis is maintained by insulin-producing β-cells and glucagonproducing α-cells [3]. Increased blood glucose levels causes insulin secretion from βcells, uptake and storage of excess glucose in skeletal muscle and adipose tissue, and
lowering of blood glucose concentration [3]. Conversely, when blood glucose levels fall
below baseline, insulin secretion is halted and amino acids are released, signaling α-cells
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to secrete glucagon [3]. Glucagon signals to the liver to break down stored glucose
through the processes of gluconeogenesis and glycogenolysis, resulting in an increase in
blood glucose concentration [6]. The opposing processes induced by glucagon and insulin
act to maintain proper blood glucose homeostasis.
In order to develop novel therapies for type II diabetes, knowledge of normal
pancreatic endocrine cell development and maintenance is critical. Previous studies have
demonstrated the crucial role transcription factors play in endocrine specification and
maintenance [1]. During development, ablation of essential transcription factors leads to
loss of cell fate specification and/or maintenance [1]. However, in adult animals
pancreatic cell fate is more defined, and ablation of transcription factors is less likely to
result in complete loss of cell fate [1]. Cell fate is maintained in mature endocrine cells
through a combination of a complex transcriptional program and extensive chromatin
modifications [7].
In endocrine α-cells, one such crucial transcription factor required for proper
specification and maintenance is the homeodomain-containing protein aristaless-related
homeobox gene (Arx) [8]. Ablation of Arx during development results in the complete
loss of the α-cell lineage and reallocation of presumptive α-cells into β- and δ-cell fates
[8,9]. Furthermore, forced misexpression of Arx in the developing pancreas or islets
leads to conversion of β- and δ-cells into α- and PP-cell fates [10]. Thus, Arx is
necessary and sufficient for α-cell specification.
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Arx is also necessary for neonatal α-cell fate maintenance [9]. Arx is exclusively
expressed in glucagon+ α-cells at all time points examined after specification [8]. Loss of
Arx in glucagon+ α-cells results in conversion of Arx-ablated α-cells into a β-like cell fate
through an insulin+glucagon+ bihormonal intermediate [9]. However, short-term ablation
of Arx in mature α-cells does not result in loss of α-cells or misexpression of other
endocrine hormones [9].
This previous study characterized the role of Arx in maintenance of neonatal αcell fate and began to explore this role in mature α-cells [9]. Although short-term (2
weeks) ablation of Arx in mature α-cells does not result in a visible phenotype, the longterm (~8 weeks) impact of this ablation has not been explored. Here, we demonstrate
that long-term ablation of Arx in mature α-cells results in improved glucose tolerance,
gradual weight loss, and misexpression of insulin and PP, but not somatostatin, in
glucagon+ cells. In vitro secretion studies of Arx-ablated islets demonstrate loss of
glucagon secretion in response to incubation with a mixed amino acid solution and
instead insulin is secreted in response to α- and β-cell stimuli. Additionally, Arx-ablated
islets display severely reduced glucagon content. These results suggest that long-term
ablation of Arx in adult α-cells leads to loss of proper cell fate maintenance and
conversion of α-cells into an α-β-PP hybrid cell that no longer secretes glucagon, but
instead produces and secretes insulin in response to both α- and β-cell stimuli.
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Results:
Ablation of Arx in adult animals leads to improved glucose tolerance
Short-term ablation (2 weeks) of Arx using a global, tamoxifen-inducible mouse
model has been previously described [9]. To determine the long-term consequence
associated with ablation of Arx in adult mice, the same mouse model was utilized. Twomonth old control, ArxL/Y;pCAGG-CreER male, and ArxL/L;pCAGG-CreER female (IKO
from here on) mice were induced with tamoxifen then analyzed by glucose tolerance tests
(GTT) every two weeks to monitor changes in glucose homeostasis over time.
Two weeks post-induction, control and IKO mice demonstrated similar blood
glucose levels after an overnight fast (Fig. 3.1A). However, IKO mice had significantly
lower fasting blood glucose levels four and six weeks post induction when compared to
controls (Fig. 3.1B-C). Interestingly at eight weeks post induction IKO mice no longer
demonstrated significantly lower fasting blood glucose levels, though the data were
approaching significance (Fig 3.1D).
Similar to the fasting blood glucose levels, IKO mice demonstrated a slightly, but
not significantly, improved glucose tolerance starting at four weeks post induction (Fig.
3.1B-D). Two weeks post induction control and IKO mice demonstrated similar glucose
tolerances (Fig. 3.1A). While control and IKO mice peaked at relatively the same blood
glucose level during GTT, IKO mice returned to baseline faster.
Starting at 6 weeks post-induction, IKO mice began to display diarrhea, weight
loss, and eventually rectal discharge (data not shown). On average, control mice gained
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around 2g after induction (Fig 3.1E). Conversely, IKO mice began to lose weight
starting at six weeks and weighed significantly less than controls by eight weeks post
induction.
However, Arx is also required for proper enteroendocrine cell specification [11].
The model utilized in this study is a global ablation model resulting in ablation of Arx in
the pancreas as well as the intestine. Thus, it is likely that the physiological data
presented are due to ablation of Arx in the intestine as well as the pancreas. However,
when taken together, these data suggest that while short-term ablation of Arx does not
result in a visible phenotype, long-term ablation of Arx results in improved glucose
tolerance and weight loss. To examine the pancreas specific defects associated with
ablation of Arx in mature α-cells immunohistochemistry and in vitro assays were
performed.
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Figure 3.1: IKO animals display improved glucose tolerance and weight loss over
time
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Figure 3.1: IKO animals display improved glucose tolerance and weight loss over
time (A-D): Glucose tolerance tests for control (black circles) and IKO mutant mice
(white boxes) two(A), four(B), six(C), and eight(D) weeks after ablation of Arx. Results
are graphed as blood glucose levels measured at 0, 15, 30, 60, 90, and 120 minutes after
injection of a bolus of glucose. (E): Change in weight from initial induction to six and
eight weeks post induction. Results are graphed as change in weight with controls
represented by the black bars and IKO mutants represented with the white bars. All
results are presented as ±SEM with (*) denoting significance where p<0.05. Nonsignificant data p values are indicated on corresponding charts. Five control and five IKO
mice were utilized for each experiment.

92

IKO glucagon+ α-cells misexpress insulin and PP, but not somatostatin, eight weeks
after ablation of Arx
Previous studies have demonstrated that short-term ablation of Arx does not result
in loss of α-cells or significant misexpression of other endocrine hormones even with
complete loss of Arx expression [9]. To determine if a long-term ablation of Arx results
in a pancreatic phenotype, control and IKO pancreata were examined nine weeks post
induction for the presence, localization, and segregation of glucagon, insulin,
somatostatin, and PP. Similar to the previous study, no apparent change in the quantity
or localization of glucagon+ cells was noted in IKO mice (Fig 3.2). However, in contrast
to short-term ablation of Arx, long-term ablation resulted in the misexpression of insulin
and PP in glucagon+ cells (Fig 3.2 A, B, E, F). No co-expression was noted in control
animals. Approximately 50% of glucagon+ cells in IKO animals co-expressed the
endocrine hormone insulin. Furthermore, a few α-cells were also noted to co-express PP
and glucagon. Conversely, no misexpression of somatostatin was noted in control or
IKO pancreata (Fig 3.2C-D). These data demonstrate that long-term ablation of Arx in
adult animals does not result in loss of glucagon+ α-cells, but does result in misexpression
of the endocrine hormones insulin and PP in a subset of α-cells in IKO mice.
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Figure 3.2: 9 weeks after ablation of Arx, glucagon+ cells coexpress the endocrine
hormones insulin and PP, but not somatostatin
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Figure 3.2: 9 weeks after ablation of Arx glucagon+ cells coexpress the endocrine
hormones insulin and PP, but not somatostatin. (A-F): Control (left) and IKO (right)
pancreatic sections were stained for glucagon (green) and insulin (red, A-B), somatostatin
(red, Sst, C-D), and PP (red, E-F). No change in the number of glucagon+ cells was
apparent in IKO animals. However, many glucagon+ cells coexpressed the endocrine
hormones insulin and PP, but not somatostatin. Images are representative from five
controls and five IKO animals utilized for each experiment. (*) represent autoflourescing
blood cells not real signal. Arrows point to copositive cells. Enlarged image in upper left
hand corner represents boxed in cells in corresponding image.
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IKO islets display loss of glucagon secretion and improper insulin secretion in
response to α-cell stimuli
Given the striking bihormonal phenotype in α-cells upon Arx ablation in the adult
pancreas, it was crucial to determine if these mutant islets still properly secrete hormones
in response to glucose and amino acid stimulation. Further, since IKO animals
demonstrate diarrhea and weight loss from an intestinal phenotype, we utilized in vitro
secretion assays to isolate islet function from that of the intestinal phenotype. Control
and IKO islets were incubated with either media (no stimulation), a 4mM mixed amino
acid solution (stimulates glucagon secretion), or a 10mM glucose solution (stimulates
insulin secretion). After stimulation, insulin or glucagon secretion was measured.
Glucagon secretion in vitro assays demonstrated that control islets secreted
glucagon upon stimulation with a mixed amino acid solution, but not a glucose solution
(Fig. 3.3A). However, IKO islets had a lower basal level of glucagon secretion and failed
to secrete glucagon in response to a mixed amino acid solution (Fig 3.3A). This finding
demonstrates loss of glucagon secretion upon long-term ablation of Arx.
To further characterize the secretion properties of IKO islets insulin secretion in
vitro assays were performed. Control islets released insulin in response to a 10mM
glucose solution, but not a mixed amino acid solution (Fig 3.3B). Conversely, IKO islets
released insulin when stimulated with both a 10mM glucose and 4mM amino acid
solution (Fig 3.3B). This result demonstrates that long-term ablation of Arx results in
improper insulin secretion in IKO islets.
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Finally, insulin and glucagon content was measured in control and IKO isolated
islets. While insulin content was similar between control and IKO islets, glucagon
content was drastically reduced in IKO islets when compared to controls (Fig. 3.3C-D).
When taken together, these data demonstrate loss of glucagon content and secretion upon
long-term Arx ablation in adult pancreata. Instead, Arx-ablated α-cells secrete insulin in
response to both α- and β-cell stimuli.
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Figure 3.3: IKO islets have reduced glucagon secretion and content with improper
insulin secretion
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Figure 3.3: IKO islets have reduced glucagon secretion and content with improper
insulin secretion. (A-B): In vitro insulin (A) and glucagon (B) secretion assay for control
(black bars) and IKO (white bars) islets in response to media (G0, no stimulation), a 4.0
mM mixed amino acid solution (AAM, glucagon secretion), and a 10mM glucose
solution (G, insulin secretion). Results are graphed as ng of insulin or pg of glucagon
secreted per 50 islets in 30 minutes. (C-D): Insulin (C) and glucagon (D) content in
control (black bar) and IKO (white bar) islets. Results are graphed as ng of insulin/pg of
glucagon per islet. All results are graphed as ± SEM with (*) denoting significance
where p≤0.05. n.s. indicates results that are not significant. Above studies were
performed by Dr. ChangHong Li
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Discussion:
The data presented here demonstrate loss of proper α-cell fate maintenance upon
long-term ablation of Arx in adult mice. Eight weeks after tamoxifen induction, IKO
mice demonstrate improved glucose tolerance, misexpression of insulin and PP, loss of
glucagon secretion and content, and gain of insulin secretion in response to α-cell stimuli.
These data suggest that ablation of Arx results in loss of α-cell fate and conversion of
these cells into an α-β-PP hybrid cell that expresses multiple hormones, but exclusively
secretes insulin in response to both α- and β-cell stimuli. Overall, these results expand
the previously defined role for Arx, and demonstrate that Arx is necessary for cell fate
maintenance in mature α-cells.

An α-cell specific ablation of Arx is essential to determine pancreas specific
physiological defects.
The data presented here were obtained using a global, tamoxifen-inducible
transgenic mouse model, resulting in ablation of Arx in the entire animal upon
administration of tamoxifen. Prior studies have demonstrated that Arx is necessary for
the proper development and maintenance of several different tissues, including the brain,
digestive tract, testis, muscle, and pancreas [8,11,12,13,14]. Thus, the physiological
defects described here, such as improved glucose tolerance, weight loss, and diarrhea,
cannot be attributed solely to loss of Arx in the pancreas. Rather, it is likely that these
observed phenotypes are due to the ablation of Arx in multiple tissue types, especially the
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digestive tract. However, the immunohistochemistry and in vitro secretion assays
performed demonstrate a clear pancreas specific defect separate from that of the intestine.
These studies allowed pancreas specific analysis of the phenotype and demonstrate that
long-term ablation of Arx in mature α-cells results in loss of cell fate maintenance.
Future studies utilizing an α-cell specific model will clarify the physiological, pancreas
specific, defects, as well as uncover other less severe phenotypes not observed in this
global study.

Long-term ablation of Arx in mature α-cells results in loss of cell fate maintenance.
We first demonstrated that short-term (2 weeks) ablation of Arx in adult mice
does not result in loss of α-cells or misexpression of other endocrine hormones [9]. We
demonstrate that, using the same model, eight weeks post induction the majority of αcells express multiple hormones, have lost glucagon secretion and content, and
improperly secrete insulin in response to α-cell stimuli. These data demonstrate that Arx
is necessary for long-term α-cell fate maintenance and function in mature α-cells.
While no apparent defects were noted 2 weeks post induction, Arx-deficient αcells were likely beginning to lose control of cell fate maintenance. However, there are
other cellular mechanisms in place to help maintain α-cell fate. Previous studies have
demonstrated that mature α-cells have a vast landscape of activating and repressing
chromatin marks [15]. This landscape aids in maintaining the proper transcriptional
program in addition to expression of the correct transcription factors and proteins [15]. A
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situation can be imagined where, upon ablation of Arx, other transcription factors and the
remaining chromatin structure are able to maintain α-cell fate for a brief period of time.
However, in the long term, these chromatin marks begin to erode and the necessary
transcriptional programs begin to slip, resulting in loss of α-cell fate, misexpression of
other endocrine hormones, and subsequent loss of correct signaling mechanisms. Future
studies examining the role of histone modifications in mature α-cells, as well as a more
detailed description of α-cell characteristics following ablation of Arx, will clarify this
result, explore the above hypothesis, and begin to address how cell fate is maintained
short-term and long-term in the mature endocrine pancreas.

Arx-ablated α-cells respond to both α- and β-cell stimuli by secretion of insulin.
In vitro stimulation of endocrine islets with glucose and amino acids is an
accurate and sensitive way to examine insulin and glucagon secretion, respectively [16].
Control islets responded correctly to each stimulus, secreting insulin in response to a
glucose solution and glucagon in response to a mixed amino acid solution. However,
IKO islets improperly responded to both stimuli, failing to secrete glucagon in response
to amino acids and instead secreting insulin in response to both glucose and amino acids.
This result indicates that upon ablation of Arx, α-cells begin to resemble an α-βPP hybrid cell that is able to respond via insulin secretion to both α- and β-cell stimuli.
Although ablation of Arx leads to loss of α-cell fate maintenance and glucagon secretion,
it does not result in loss of glucagon+ α-cells as seen upon neonatal ablation [9]. Future
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studies examining a longer chase period after ablation of Arx will be useful in
determining if these hybrid cells eventually lose glucagon expression and acquire a pure
β-cell phenotype. Alternatively, these cells could remain trapped in an intermediate fate
and continue to secrete insulin in response to both α- and β-cell stimuli.
Additionally, these data will be useful in developing novel treatments for type II
diabetes. Because type II diabetes results from inadequate insulin supply combined with
excess glucagon secretion, therapies utilizing endogenous α-cells and transdifferentiating
them into functional β-cells would present an ideal therapy [2,4]. If Arx-ablated α-cells
eventually differentiate into a pure β-cell fate, this result can then be expanded as a
possible novel treatment for diabetic patients.

Conclusion
The data presented here demonstrate an essential role for Arx in the maintenance
of mature α-cell fate. Long-term ablation of Arx in adult animals leads to loss of α-cell
fate maintenance. IKO mice display an improved glucose tolerance over time as well as
diarrhea and weight loss. Phenotypic analysis determined co-expression of insulin and
PP in glucagon+ cells. In vitro secretion assays showed loss of glucagon secretion.
However, the IKO islets were able to secrete insulin in response to amino acids which
normally only stimulates glucagon secretion. These results demonstrate that Arx is
necessary for α-cell fate maintenance. Future α- to β-cell transdifferentiation therapies
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for type II diabetes focused on the role of Arx in α-cell fate may provide an avenue for
endogenous restoration of normal blood glucose homeostasis.
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Materials and Methods:
Animals and Breeding Strategy
The derivation of the Arx floxed and pCAGG-CreER transgenic lines has been
previously described [17,18]. IKO mice were generated by crossing heterozygous
ArxL/+;pCAGG-CreER females to ArxL/Y males. IKO mutant mice consisted of
ArxL/Y;pCAGG-CreER males and ArxL/L;pCAGG-CreER females. Control mice
consisted of littermate sex-matched animals, both male and female, including Arx+/Y,
Arx+/Y;pCAGG-CreER, ArxL/Y, ArxL/+, ArxL/+;pCAGG-CreER, and ArxL/L. No
significant differences were noted between any control animals in terms of pancreatic and
islet size, weight, or morphology. Male and female IKO animals were phenotypically
identical and used interchangeably in this study.

Immunohistochemistry
Dissections were performed in cold 1X PBS. The entire pancreatic tissue was
removed, weighed, and submerged in cold 4% PFA/PBS overnight at 4°C. Tissue was
then rinsed, dehydrated, embedded in paraffin, and sectioned at 8 µm on charged glass
slides. Immunohistochemistry was performed using 10 mmol citric acid buffer (ph 6.0)
for antigen retrieval followed by blocking endogenous protein using CAS-Block reagent
(Invitrogen). Primary antibodies were added and slides incubated overnight at 4°C.
Primary antibodies used were: Insulin (MS 1:400, Thermo Scientific and GP 1:1000,
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Abcam), Glucagon (GP 1:3000, Millipore and Rb 1:1000, Chemicon), Somatostatin (Rb
1:200, Invitrogen), and PP (Rb 1:200, Invitrogen)

Tamoxifen Induction
Two-month old IKO and matched littermate controls were injected with 50 µg/g
body weight of 10 mg/ml tamoxifen solution to induce Cre expression. Tamoxifen was
dissolved in a solution of 10% ethanol and 90% sunflower seed oil (Sigma). IKO and
control animals consisted of both male and female mice. Injections were intraperitoneal
and performed on three consecutive days followed by a specified chase period (2-8 weeks
post induction).
Alternatively, induction was accomplished using an oral gavage system with the
same concentration of tamoxifen solution and induction strategy previously described.
Both methods resulted in similar ablation with no significant differences observed.

Glucose Tolerance Test
Glucose homeostasis was examined using an intraperitoneal glucose tolerance
test. Mice were fasted overnight and injected with a bolus of glucose (2g/kg body
weight, Sigma). Blood glucose levels were measured at 0, 15, 30, 60, 90, and 120
minutes post injection using an automatic glucometer (One Touch Ultra; LifeScan).
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Islet Isolation and Culture
Control and IKO islets were isolated via collagenase digestion. Once isolated
islets were cultured in 10mM glucose RMPI 1640 media (Sigma) for three to four days.
Culture media consisted of 2mM glutamine, 100units/ml penicillin, and 50µg/ml
streptomycin. Islets were maintained at 37°C. Islet Isolation studies were performed by
Dr. ChangHong Li of the Children's Hospital of Philadelphia.

In vitro Secretion Assays
50 islets from each control and IKO animal were placed in 96-well plate, preincubated in warmed KRBB (115mM NaCl, 24mM NaHCO3, 5mM KCl, 1mM MgCl2,
2.5mM CaCl2, pH 7.4) buffer for 30 minutes at 37°C, and than stimulated with either a
4.0mM mixed amino acid solution or a 10mM glucose solution for 30 minutes at 37°C.
Supernatant was removed from well and glucagon secretion measured (Cisbio glucagon
kit) or diluted 10X and insulin secretion measured (Cisbio insulin kit). Molecular Devices
M5e plate reader was utilized to measure glucagon and insulin.

Insulin and Glucagon Content
Islets were isolated and washed 2X in cold 1X PBS in 96-well plate. 100µl
homogenization buffer (10mM Trisma, 10mM Sodium Acetate, 10µM EDTA, 1% Triton
X-100, pH 7.4) was added, islets were homogenized, and diluted 100X for glucagon
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content or 2000X for insulin content. Molecular Devices M5e plate reader was utilized
to measure insulin and glucagon content.

Statistical Analysis
All results are graphed as ± the standard error of the mean (SEM). In all
calculations significance was determined using a two-tailed Student’s t-test where p≤0.05
was considered significant. Other p values that did not reach significance, but were
deemed meaningful are displayed on the corresponding graphs/charts.
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CHAPTER IV:
Arx polyalanine expansion in mice leads to reduced pancreatic α-cell
specification and increased α-cell death
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Abstract
ARX/Arx is a homeodomain containing transcription factor necessary for the
specification and early maintenance of pancreatic endocrine α-cells. Many transcription
factors important to pancreas development, including ARX/Arx, are also crucial for proper
brain development. Although null mutations of ARX in human patients result in the
severe neurologic syndrome XLAG (X-linked lissencephaly associated with abnormal
genitalia), the most common mutation is the expansion of the first polyalanine tract of
ARX, which results primarily in the clinical syndrome ISSX (infantile spasms).
Subsequent mouse models of XLAG, ISSX and other human ARX mutations demonstrate
a direct genotype-phenotype correlation in ARX-related neurologic disorders.
Furthermore, mouse models utilizing a polyalanine tract expansion mutation have
illustrated critical developmental differences between null mutations and expansion
mutations in the brain, revealing context-specific defects. Although Arx is known to be
required for the specification and early maintenance of pancreatic endocrine α-cell, the
consequence of a polyalanine expansion has not been explored.
We report here that mice with an expansion mutation in the first polyalanine tract
of Arx have impaired α-cell specification and maintenance with apoptosis playing a
critical role in gradual α-cell loss. This finding is novel and distinct from what was
reported in mice with germ-line Arx null mutation, in which α-cells were re-specified into
β- and δ-cells. Overall, this analysis of an Arx polyalanine expansion mutation on
pancreatic development further defines the critical nature of timing in α-cell specification
and maintenance.
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Introduction
Aristaless-related homeobox gene (Arx) encodes a homedomain containing
transcription factor that is expressed in the brain, testis, muscle, pancreas, and digestive
tract [1,2]. In the brain, Arx is essential for the proper development and migration of
GABA-ergic interneurons and has a role in cortical ventricular zone proliferation [3,4].
In humans, various mutations of ARX result in a spectrum of neurologic disorders, the
most severe clinical presentation being X-linked lissencephaly associated with abnormal
genitalia (XLAG) [5]. XLAG, which has been linked to null and missense mutations in
ARX, is characterized by a severe brain malformation, termed lissencephaly, corpus
callosum agenesis, neonatal-onset intractable epilepsy, and early death [6]. Arx null mice
phenocopy the clinical presentation of XLAG patients, displaying cortical brain
malformations and agenesis with lethality within 24-hours of birth [3,4]. Histological
and molecular analyses reveal a dual function for Arx in radial and tangential migration
of GABA-ergic interneurons in mice [7].
Interestingly, polyalanine expansion mutations are the most common ARX
mutations found in human disease [8]. ARX contains four polyalanine repeat tracts
spaced throughout the protein [9]. It is the first two polyalanine repeats that are most
often expanded in human disease [10]. Patients with these expansion mutations present
with severe neurologic phenotypes, including seizures and mental retardation, but without
brain malformations [11]. Expansion of the first polyalanine tract by an additional seven
alanines has been associated with West Syndrome or infantile spasms (ISSX) [12].
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Analyses using genetically modified mouse models have been performed to
explore the impact different ARX polyalanine expansion mutations have on neuronal
development and cognitive functionality; these models demonstrate a similar genotypephenotype correlation to humans [13]. Specifically, mouse models with an expansion
mutation of the first polyalanine tract of Arx reveal that only tangential migration of
GABA-ergic interneurons is lost, with no significant impact to radial migration [14,15].
Thus, it appears that expansion of the first polyalanine tract of Arx results in context
specific defects in neural development.
In addition to the profound effects ARX/Arx mutations have on the brain, it also
has a severe impact on the development of other organs. Of note, Itoh and colleagues
recently described complete loss of glucagon-producing α-cells in the pancreas of an
ARX-null XLAG patient [16]. The mammalian pancreas contains an endocrine and
exocrine compartment that functions to produce and secrete hormones and enzymes
necessary for glucose homeostasis and digestion, respectively [17]. The endocrine
compartment is organized into Islets of Langerhans with a core of insulin-producing βcells and a surrounding mantle of α-, δ-, ε-, and PP-cells producing the hormones
glucagon, somatostatin, ghrelin, and pancreatic polypeptide, respectively [18]. Arx is
expressed in Ngn3+ endocrine progenitors and then restricted to the α-cell lineage where
it is expressed throughout the life of the animal [2]. Loss of glucagon-producing α-cells
in XLAG patients suggests that ARX is necessary for specification and/or maintenance of
this endocrine cell population [16]. Similar observations in the pancreas were also
reported in Arx null mice in which a complete loss of α-cells was detected [2,19].
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Without Arx function, α-cells are lost while β- and δ-cells simultaneously increase
without a change in total endocrine mass [2]. Recently, lineage tracing of these Arx
ablated α-cells has demonstrated that removal of Arx in glucagon+ cells results in
conversion into an insulin+ β-like fate through a bihormonal intermediate [20].
Interestingly, this conversion of α-cells into non-α-cell fates was only seen with loss of
Arx during the neonatal period, not in adulthood [20].
Previous work has suggested a dual role for Arx in both specification of α-cells
and repression of β- and δ-cell fate. However, no studies have investigated the effects of
the more common polyalanine expansion mutation on endocrine pancreas α-cell
specification and maintenance. Here we show that pancreatic defects associated with this
Arx expanded mouse model (ArxE) are also context specific. Our results demonstrate a
reduced number of glucagon-expressing α-cells in ArxE pancreata, suggesting impaired
α-cell specification. However, a subset of α-cells is specified in ArxE mice and these
cells do not express other hormones or β-cell specific transcription factors, indicating
correct fate determination. Conversely, maintenance of this subset of α-cells is impaired,
and these cells are gradually lost through apoptosis over time. Furthermore, unlike Arx
null mutations, no change in β- or δ- cell mass is observed, suggesting that an expanded
Arx protein is still capable of blocking other, non-α-cell fates.
These results describe a unique pancreatic phenotype associated with an Arx
polyalanine expansion mutation and further illustrate the genotype-phenotype correlation
associated with different forms of ARX/Arx mutations. Taken together, these findings
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help elucidate our understanding of Arx-related syndromes outside of the brain as well as
characterizing the different roles of Arx in α-cell specification versus maintenance.
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Results
ArxE mice retain a subset of glucagon-producing α-cells at embryonic day (E) 15.5.
To determine the effect an Arx expansion mutation has on α-cell specification and
maintenance, hemizygous ArxExpanded/Y (referred to as ArxE from here on) mutant mice
were obtained by crossing heterozygous ArxExpanded/+ females to wild-type Arx+/Y males.
ArxE mice were born in normal Mendelian ratios with birth weights similar to their
littermate controls. However, ArxE mice displayed a slower growth curve and by
postnatal day 6 (P6) were significantly smaller than control littermates (Terry and May,
unpublished data). We did not observe any significant changes in pancreatic weight,
morphology, or histology between ArxE mice and controls at any time point (data not
shown).
To explore a possible pancreatic defect, immunostaining was performed in control
and ArxE pancreata at E15.5 to examine the presence, localization, and segregation of
each endocrine hormone. Immunostaining for glucagon demonstrated a dramatic
reduction in the number of glucagon+ α-cells at E15.5 in ArxE mice (Fig. 4.1A-F).
However, unlike Arx null animals, a subset of α-cells appeared to be specified in ArxE
mice by glucagon staining [2,19]. Furthermore, these remaining glucagon+ cells did not
coexpress insulin or somatostatin suggesting proper α-cell fate determination (Fig. 4.1AD). Co-staining for glucagon and ghrelin did reveal 30% colocalization in both control
and ArxE pancreata, similar to what has been previously described in wildtype pancreata
(Fig. 4.1E-F) [21]. PP-cells are not normally present at E15.5 and immunostaining for
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glucagon and PP did not reveal any precocious specification of this cell type in ArxE
mice (data not shown) [17]. Consistent with our qualitative analysis, morphometric
studies showed that while α-cell mass is significantly decreased to 20% of wild-type
levels, no change in β- or δ-cell mass was observed (Fig. 1G). Furthermore, total
endocrine mass was not significantly altered at this time point.
Although the endocrine mass of β- and δ-cells was not changed, we also measured
the expression levels of the hormone genes in ArxE mice using quantitative PCR (qPCR).
The expression level of glucagon was significantly reduced in ArxE pancreata, as
expected (Fig. 1H). However, both insulin and somatostatin transcript levels were
significantly upregulated in ArxE pancreata when compared to littermate controls (Fig.
4.1H). No significant difference in the expression level of PP was observed in ArxE
mice, further indicating that there was no precocious expression of PP upon ArxE
mutation (Fig. 4.1H). Since β- or δ-cell mass is not increased, our qPCR results suggest
that there is a significant upregulation of hormone gene expression within the respective
endocrine cells. These data demonstrate that the majority of α-cell specification is
impaired in ArxE mice but, for a subset of α-cells that are specified, fate determination
appears intact without any misexpression of other endocrine hormone populations within
the α-cells, unlike Arx null mouse models.
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Figure 4.1: ArxE mice are able to specify a subset of α-cells at E15.5
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Figure 4.1: ArxE mice are able to specify a subset of α-cells at E15.5. (A-F): Control
and ArxE E15.5 pancreatic sections were stained for glucagon (green) and insulin (red;
A-B), somatostatin (Sst; red; C-D), and ghrelin (Ghr; red; E-F). Scale bar denotes 50µm.
(G): Quantification of total endocrine (ChrgA) and β-, δ-, and α-cell mass in control
(black bar) and ArxE (white bar) pancreata. (H): Quantification of transcript levels for
each endocrine hormone in control (black bar) and ArxE pancreata (white bar) at E15.5
using qPCR. All results are graphed as fold change relative to littermate controls ±
standard error of the mean. Significance is denoted with (*) when p<0.05. All analysis
consists of 4-5 animals per group.
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By P14, the α-cell lineage is profoundly lost in ArxE pancreata
To determine the fate of this remaining subset of α-cells in ArxE mice, control
and ArxE P14 pancreatic sections were examined for the expression of each endocrine
population. Morphometric analysis showed that α-cell mass is reduced by 99.5% with
only a few single glucagon+ cells remaining (Fig. 4.2A-H, J). Immunostaining and
quantification of β-, δ-, PP-, and ε-cell mass at P14 did not reveal any significant
differences in quantity or localization of these endocrine cell types in ArxE mice (Fig.
4.2A-I). Finally, we observed a significant 30% reduction in total endocrine mass in P14
ArxE mice as measured by Chromogranin A staining (Fig. 4.2I). This reduction is likely
the result of the drastic loss of α-cells in the ArxE mice at this age. These data suggest
that α-cells are lost in ArxE mutant mice and not reallocated to a β- or δ-cell fate.
To examine when the loss of the α-cell lineage occurs, we measured α-cell mass
in embryonic and postnatal pancreata, starting at E15.5 (Fig.4. 2J). As previously
described, a subset of α-cells is properly specified in E15.5 ArxE pancreata; however,
these cells are gradually lost over time. From our morphometric analyses of E15.5,
E18.5, P0 and P14 pancreata, we conclude that this α-cell population is not maintained,
and is lost in a temporal manner without reallocation to a β- or δ-cell fate, resulting in a
significant reduction in total endocrine cell mass.
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Figure 4.2: ArxE mice have almost complete loss of α-cell fate by P14 with a
concomitant decrease in total endocrine mass, but no change in β- and δ-cell mass
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Figure 4.2: ArxE mice have almost complete loss of α-cell fate by P14 with a
concomitant decrease in total endocrine mass, but no change in β- and δ-cell mass.
(A-H): P14 pancreatic sections were stained for glucagon (green) and insulin (red; A-B),
somatostatin (Sst; red; C-D), PP (red; E-F), and ghrelin (Ghr; red; G-H). Scale bar
denotes 50µm. (I): Quantification of endocrine hormone mass including total endocrine
mass (ChrgA), insulin, somatostatin, PP, and ghrelin displayed as fold change in ArxE
mice (white bar) relative to control (black bar). (J): Analysis of glucagon mass over time
starting at E15.5 and ending at P14 in control (black bar) and ArxE (white bar) pancreata.
Resulting p value is listed. (*) denotes significance where p<0.05. Error bars represent
standard error of the mean (I, J). For all analysis 4-5 animals per group were analyzed
with all ArxE mice being males and control mice consisting of male and female mice.
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ArxE α-cells do not express β-cell specific transcription factors
To further examine whether α-cell specification is properly executed in ArxE
pancreata, qPCR analysis was used to analyze the expression of α- and β-cell specific
transcription factors in ArxE and control pancreata at E15.5. The α-cell specific
transcription factors Arx and Brn4 were significantly downregulated in ArxE mice to
approximately 30% of wild-type levels (Fig. 4.3A). This downregulation is similar to the
reduction in α-cell mass and is likely the result of having fewer α-cells expressing these
transcription factors. Strikingly, examination of β-cell specific factors MafA, Glut2,
Pdx1, and Pax4 demonstrated a significant upregulation of MafA and Glut2 while Pdx1
and Pax4 levels were not altered (Fig. 4.3A).
To determine if the significant upregulation of MafA and Glut2 mRNA levels in
ArxE mice results in misexpression of these factors in α-cells, immunostaining for
glucagon, Pdx1, Glut2, and MafA was performed (Fig. 4.3B-G). Similar to control
animals, no colocalization of glucagon with Pdx1, Glut2, or MafA was observed in ArxE
pancreata at E15.5 (Fig. 4.3B-G). These data indicate that while an Arx expansion
mutation results in upregulation of MafA and Glut2 transcript levels, this change does not
lead to misexpression of the protein in ArxE E15.5 glucagon+ α-cells. When combined
with previous results, this result indicates that α-cell fate determination has occurred
normally in the remaining glucagon+ cells.
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Figure 4.3: Specified α-cells in ArxE mice do not misexpress β-cell specific
transcription factors at E15.5
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Figure 4.3: Specified α-cells in ArxE mice do not misexpress β-cell specific
transcription factors at E15.5. (A): Quantification of transcript levels for α- and β-cell
specific transcription factors graphed as fold change in ArxE pancreata (white bar)
relative to littermate control (black bar). Error bars represent standard error of the mean.
Significance, when p≤0.05, is denoted with (*). (B-G): Control and ArxE E15.5
pancreatic sections were stained for glucagon (green) and Pdx1 (red; B-C), Glut2 (red; DE), and MafA (red; F-G). Five specimens were analyzed for each group and
representative images taken. (*) denotes autofluorescence of red blood cells. Scale bar
denotes 50µm.
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ArxE pancreata contain more apoptotic glucagon+ cells
There are two possible causes for the apparent loss of α-cells in ArxE pancreata:
reduced proliferation or increased apoptosis. Proliferation was measured by examining
the localization and quantity of proliferating glucagon+ α-cells using the proliferation
marker Ki67. No change in the number of proliferating, Ki67+ α-cells was noted in ArxE
mice when compared to control littermates at E15.5 (Fig. 4.4A-B). Furthermore,
expression analysis using qPCR for Ki67 and Birc5 (another proliferation marker) did not
reveal any differences in the expression level between control and ArxE pancreata (Fig.
4.4C). These data demonstrates that α-cells proliferate normally in ArxE mice at E15.5.
To explore whether changes in the rate of apoptosis may have contributed to αcell loss we performed TUNEL assays. Co-immunostaining for glucagon and TUNEL
demonstrated an increase in the number of TUNEL+/glucagon+ cells in ArxE pancreata at
E15.5 (Fig. 4.4D-E). Quantification of the percentage of glucagon+ that were TUNEL+ in
control and ArxE pancreata demonstrated a significant and profound increase in the
percent apoptotic α-cells in ArxE pancreata (Fig. 4.4F). Taken together, these results
demonstrate that an increase in apoptosis is the major contributor to the temporal α-cell
loss seen in ArxE pancreata.
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Figure 4.4: There is a drastic increase in the percentage of apoptotic glucagon+ cells
in ArxE mice, but no apparent change in proliferation
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Figure 4.4: There is a drastic increase in the percentage of apoptotic glucagon+ cells
in ArxE mice, but no apparent change in proliferation. (A-B): Control and ArxE
E15.5 pancreatic sections were stained for glucagon (green) and Ki67 (red). Scale bar
denotes 50µm. (C): qPCR analysis for two markers of proliferation, Ki67 and Birc5, in
E15.5 control (black bar) and ArxE pancreata (white bar). Results are graphed as fold
change relative to littermate control ± the standard error of the mean. (D-E): Control and
ArxE E15.5 pancreatic sections were stained for glucagon (green) and TUNEL (red).
Arrow points to TUNEL+ cell. Scale bar denotes 10µm. (F): Quantification of the
percentage TUNEL+glucagon+ cells over total counted glucagon+ cells in control and
ArxE E15.5 pancreatic sections. All glucagon+ cells in five different pancreatic sections
from both control (black bar) and ArxE (white bar) mice were counted and determined to
be TUNEL positive or negative. The percentage of TUNEL+glucagon+ cells was
calculated and graphed as ± standard error of the mean. (*) denotes significance where
p≤0.05. Between 4 and 5 animals were examined per group for each analysis.
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Discussion
This study demonstrates that expansion of the first polyalanine tract of Arx results
in impaired specification and maintenance of endocrine α-cells through a mechanism of
programmed cell death, as opposed to α-cell fate re-specification. We show that only a
subset (20%) of α-cells is present in E15.5 ArxE pancreata. However, these glucagon+ αcells are not maintained over time and eventually undergo apoptosis, leading to a
complete absence of the α-cell lineage and a significant decrease in total endocrine cell
mass by P14. While cell proliferation is a major mechanism to expanding α-cell mass
during development, we did not detect a significant change in the rate of proliferation in
ArxE pancreata. These findings suggest that programmed cell death is the principal
cause, after initial specification, for α-cell loss in ArxE mice (Fig. 4.5).
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Figure 4.5: ArxE mice are able to correctly specify a subset of α-cells, but α-cells are
gradually lost through apoptosis
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Figure 4.5: ArxE mice are able to correctly specify a subset of α-cells, but α-cells are
gradually lost through apoptosis. Model demonstrating normal proliferation, but
increased apoptosis in ArxE mice. Normal proliferation during embryonic time points
maintains the α-cell lineage by replacing cells lost to apoptosis. However, proliferation
slows during the neonatal stage leading to loss of the α-cell lineage.
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ArxE mice reveal context specific defects in α-cells that differ from Arx null mice.
Our study reveals a novel and unique impact of ArxE mutations on the pancreas.
Phenotypes found in ArxE mice differ from those reported in the Arx null mouse models:
1) there is no change in β- and δ-cell mass, 2) there is a significant reduction in total
endocrine cell mass, and 3) a small number of α-cells are present during embryogenesis
[2]. Arx null mutations result in loss of α-cell specification in which glucagon+ cells are
never present, even at embryonic time points [2]. Loss of Arx in these endocrine
progenitors results in loss of specification and reallocation of these cells into a β- or δ-cell
fate, thus maintaining total endocrine mass [2]. Conversely, ArxE mice are able to
specify a small subset of α-cells and, more importantly, repress non-α-cell fates,
including β and δ. This retained repressive ability results in normal β- and δ-cell mass
even with the eventual complete loss of the α-cell lineage. Finally, α-cells in ArxE mice
are not able to maintain their fate, as these α-cells are gradually eliminated over time
through apoptosis, not reallocation or reprogramming, resulting in an overall decrease in
endocrine cell mass.

ArxE mice display selective derepression similar to previous neuronal studies.
Cell culture based mechanistic studies have demonstrated that Arx associates with
the groucho-family corepressor Tle1 [22]. This association is carried out through Arx’s
octapeptide domain and results in increased repressive activity [22]. Examination of this
association in an expanded neuronal model demonstrates a decreased, but not complete
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loss, of Arx-Tle1 protein binding [23]. Furthermore, neuronal studies have demonstrated
that expansion of the first polyalanine tract of Arx results in selective derepression of a
subset of Arx targets [23]. It is hypothesized that loss of association with specific corepressors (if not Tle1 itself) results in this selective derepression [23]. Interestingly, we
show here that ArxE mice do not misexpress either the endocrine hormones insulin and
somatostatin or β-cell specific transcription factors in embryonic α-cells. Thus, it appears
that at least part of Arx’s repressive abilities are intact. Future studies using chromatin
immunoprecipitation to determine direct targets of Arx in the pancreas will serve to
clarify this finding. The increased expression of insulin, somatostatin, and β-cell markers
are in the cells where Arx is not expressed, suggesting a secondary effect.

Comparing ArxE and Arx null mouse models demonstrate a direct genotype-phenotype
correlation.
In neuronal studies, there appears to be a direct genotype-phenotype correlation
associated with various Arx mutations [24]. Our study demonstrates that this correlation
is likely to be applicable in the pancreas as well. In the brain, more severe phenotypes
are attributed to null and missense mutations of Arx [8]. In the pancreas, the Arx null
mutation has an earlier onset with complete loss of glucagon-expressing α-cells [2].
Although the α-cell population is almost completely lost by P14 in the ArxE mice, their
survival curve compared to the global null mice is improved. It is difficult to determine
if this improved survival can be attributed to the pancreatic phenotype without a tissue135

specific model. Although it has been suggested that hypoglycemia is the cause of early
fatality, blood sugar levels cannot be attributed solely to the pancreas in the setting of
diarrhea and lean body mass in the ArxE mouse model (Terry and May, unpublished
data). Complete understanding at a molecular level of why this spectrum of disease
exists in both mouse models and human patients will be essential in generating future
treatments for patients with ARX-related disorders.

Conclusion
In conclusion, this study demonstrates dual functions for Arx in α-cell gene
activation and β-cell gene repression during fate specification and maintenance. Utilizing
a mouse model with an expansion mutation of the first polyalanine tract of Arx, we
demonstrate present but impaired α-cell fate specification. Although α-cell number is
dramatically reduced, proper fate determination is observed in the remaining α-cells.
However, these cells eventually undergo apoptosis, which leads to complete loss of α-cell
fate postnatally. β- or δ-cell mass is not increased, and there is a significant decrease in
total endocrine cell mass, attributed to α-cell death. Our study begins to explore the more
common polyalanine expansion, non-null Arx mutations and the effect they have on αcell specification and maintenance. Being able to separate the dual function for gene
activation and gene repression leading to fate specification and maintenance will lead to a
better understanding of the clinical presentation of ARX-related disorders and help in
designing future therapeutic treatments.
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Materials & Methods
Ethics Statement
The Children’s Hospital of Philadelphia’s Institutional Animal Care and Use Committee
(IACUC) approved all animal experiments under the protocol number 2011-10-756.
CLM monitored all animal studies.
Animals and Breeding Strategy
The derivation of mice with an expansion mutation in the first polyalanine tract of Arx
has been described previously [15]. Since Arx is located on the X chromosome
ArxExpanded (E)/+ females were bred to Arx+/Y males to generate ArxE/Y mutant males and
ArxE/+, Arx+/+, and Arx+/Y control females and males, respectively. Above controls, both
males and females, were physiologically indistinguishable in all aspects examined and as
such were used interchangeably. Mice were mated on a C67BL/6 background. The
Children’s Hospital of Philadelphia’s Institutional Animal Care and Use committee
approved all experiments.
Immunohistochemistry and Histology
All dissections were performed in cold 1X PBS. Entire pancreatic tissue was removed,
weighed, and submerged in cold 4% PFA/PBS overnight. Tissues were rinsed in PBS,
dehydrated, embedded in paraffin, and sectioned at 8µm. Antigen retrieval was
performed in 10mmol citric acid buffer (pH 6.0) followed by blocking of endogenous
peroxidase and avidin/biotin activity with 3% H2O2 (Sigma) and avidin/biotin blocking
138

kit (Vector), respectively. Slides were incubated in primary antibody overnight at 4°C.
Primary antibodies used were: Glucagon (GP 1:3000, Millipore and Rb 1:1000,
Chemicon), Insulin (MS 1:400, Thermo Scientific and GP 1:1000, Abcam), PP (Rb
1:200, Invitrogen), Sst (Rb 1:200, Invitrogen), Ghrelin (Gt 1:200, Santa Cruz), Pdx1 (Gt
1:200, Santa Cruz), MafA (Rb 1:1000, Bethyl), Glut2 (Rb 1:1000, Millipore), and
Chromogranin A (Rb 1:3000, DiaSornin). Appropriate secondary antibodies were added
at room temperature (Vector Laboratories). For immunofluorescence, secondary
antibodies were conjugated to either Cy2 or Cy3 (Jackson Laboratories) while
immunohistochemical detection was obtained with the VECTASTAIN ABC kit and
diaminobenzidine tetrahydrocholoride (DAB) substrate (Vector Laboratories). All
images utilized in this study were obtained using a Leica DM6000B microscope.
Real-Time PCR Analysis
For expression analysis, whole pancreatic tissue was dissected in cold 1X PBS and
homogenized in 1mL TRIZOL reagent (Invitrogen). RNA was isolated using provided
protocol and cDNA synthesized using Oligo-dT, Superscript, and additional necessary
reagents (Invitrogen). All quantitative PCR (qPCR) analysis was conducted in duplicate
for each specimen including at least three biologic replicates for control and mutant
analyzed with reference dye normalization. qPCR analysis was performed using Brilliant
SYBR Green PCR Master Mix (Agilent) in the Stratagene Mx3005P Real-time PCR
machine. Changes in expression level were determined by calculating and graphing fold
change relative to control. Primer sequences are available upon request.
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Hormone Cell Quantification
Total endocrine and hormone cell mass was calculated through the use of Aperio
Software. Two sections per animal were used with four or five animals per group (both
control and ArxE) analyzed. Sections were stained for either hormone mass (glucagon,
insulin, somatostatin, PP, and ghrelin) or total endocrine mass (ChrgA) using
immunohistochemistry. After dehydration and mounting, slides were scanned into the
Aperio software and positive hormone area and total pancreatic area determined.
Hormone mass and total endocrine mass was than calculated using pancreatic weight.
All ArxE mice were males while control specimens consisted of male and female mice
(see animal breeding section above). No difference in hormone or total endocrine mass
was seen between any of the controls utilized.
Statistical Analysis
Error bars were determined as ± standard error of the mean (SEM) and all values are
displayed as ± SEM. Significance was determined using a two-tailed Student’s t-test and
results considered significant when p ≤ 0.05.
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Chapter V:
Conclusions and Future Directions
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Conclusions
Type II diabetes mellitus is a global health crisis [1]. Current therapies for this
disease, the majority of which attempt to control blood glucose levels through exogenous
insulin administration, only address the most immediate consequences of inadequate
insulin signaling [1]. Long-term therapies that restore endogenous blood glucose
homeostasis will provide patients with better control of their condition while vastly
improving quality of life [1]. One of the most attractive long-term therapies is
transdifferentiation of endogenous pancreatic endocrine α-cells into physiologically
functional β-cells [2].
This treatment option stems from the novel bihormonal view of diabetes, which
posits that both decreased insulin action and hyperglucagonemia contribute to
hyperglycemia [3]. Transdifferentiation of α- to β-cells would alleviate both of these
pathological issues by increasing β-cell numbers and insulin secretion while
simultaneously decreasing α-cell numbers and glucagon secretion. This therapy will
provide patients with long-term endogenous control of blood glucose levels and eliminate
the need for exogenous insulin administration [3].
In order to develop novel α- to β-cell replacement therapies to treat diabetes, a
complete understanding of normal α-cell development and maintenance is essential [3].
Previous studies have demonstrated the key roles transcription factors play in endocrine
cell fate specification and maintenance [1]. Knowledge of the involvement of these
factors can be utilized to manipulate α-cells in designing an effective protocol for future
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therapies [1]. My dissertation attempted to broaden knowledge of normal α-cell
specification and maintenance by examining the multi-faceted roles of the homeodomain
containing transcription factor Arx. Previous studies have demonstrated that Arx is
necessary and sufficient for α-cell specification [4,5]. However, the role of Arx in
maintenance of α-cell fate, as well as the processes that are impacted by non-null Arx
mutations during α-cell development, has not been examined.
In Chapter 2, I examined the role of Arx in maintenance of α-cell fate. I
demonstrated that ablation of Arx in glucagon+ cells during development results in loss of
proper cell fate maintenance and conversion into a β-like-cell through a glucagon+insulin+
bihormonal intermediate. By P21 the majority of Arx-ablated α-cells were only insulin+,
suggestive of transdifferentiation to a β-cell fate. Many of these newly converted cells
also expressed other β-cell markers, including MafA, Glut2, and Pdx1. Conversely,
short-term ablation (2 weeks) of Arx in adult mice does not result in loss of endocrine αcells or misexpression of other endocrine hormones. These data determined that Arx is
necessary for neonatal α-cell fate maintenance, but not for short-term cell fate
maintenance in the adult.
I expanded on these results in Chapter 3, in which I explored the impact of a longterm ablation of Arx in mature α-cells using a global, tamoxifen-inducible, transgenic
mouse model. This long-term study demonstrated that eight weeks after Arx ablation,
mutant mice had an improved glucose tolerance and had lost weight compared to
littermate controls. Pancreatic analysis revealed that while normal numbers of glucagon+
cells are present in mutant mice, many α-cells co-express other endocrine hormones,
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including insulin and PP, but not somatostatin. Additionally, insulin and glucagon
secretion studies demonstrated loss of glucagon secretion and content, as well as
improper insulin secretion in response to both α- and β-cell stimuli. When taken
together, these data determined that although Arx-ablated α-cells are capable of
maintaining glucagon expression, over time these cells lose their identity and become an
α-β hybrid cell. These hybrid cells expressed both α- and β-cell hormones, but only
secreted insulin in response to α- or β-cell stimuli, indicative of a transdifferentiation-like
process.
Finally, in Chapter 4 I explored the effect non-null Arx mutations have on proper
α-cell specification and maintenance. Using a knock-in mouse model with an expansion
mutation in the first polyalanine tract, I determined that pancreatic α-cell development is
severely impaired in these mice. However, unlike Arx null mutations, a subset of α-cells
are specified and do not misexpress other endocrine hormones or β-cell specific
transcription factors, indicating correct α-cell specification and repression of non-α-cell
fates. This subset of α-cells subsequently undergoes apoptosis, and the α-cell lineage is
lost by P14, along with a significant reduction in total endocrine mass. Together, these
studies suggest that Arx plays a dual role during α-cell specification through both
repression of non-α-cell fates and activation of α-cell fate. An expansion mutation of Arx
results in loss of activation of α-cell fate (only a subset of α-cells specified), but not
repression of non-α-cell fates (no misexpression of β-cell-specific hormones or proteins).

146

147

Future Directions
What are the cellular differences between neonatal and adult endocrine cells?
Numerous studies show that complete maturation of β-cells occurs during the first
two weeks of life [6]. Before and during this period insulin-producing β-cells are
classified as immature and cell fate is more plastic [6]. After weaning (P21) and
maturation of β-cells is complete, cell fate is more defined and cells are less likely to
convert into other cell types [6]. The end of this period is marked by the loss of MafB
and gain of MafA expression in the mature β-cell [7].
Since pancreatic endocrine cells have a common lineage, a similar maturation
period seems likely in endocrine α-cells [8]. I demonstrated phenotypic differences
between ablation of Arx in neonatal versus adult α-cells. These observed differences
could be attributed to immature versus mature α-cells and the associated plasticity in cell
fate. These data also correlate with a study examining misexpression of Pdx1 in α-cells
during late development and in mature α-cells [9]. Misexpression of Pdx1 in "immature"
α-cells led to transdifferentiation into β-cells [9]. However, misexpression of Pdx1 in
mature α-cells did not result in such a conversion [9].
When taken together, these studies suggest that cell fate maintenance is different
in neonatal versus adult α-cells. Future studies identifying differentially expressed
transcription factors will begin to characterize each state. Further experiments ablating
transcription factors at diverse time points will aid in mapping the maturation process for
endocrine α-cells.
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Likely, chromatin marks and histone modifications play an important role in this
maturation process [10]. A situation can be imagined in which newly formed endocrine
cells are largely devoid of lineage-specific histone modifications and thus more plastic.
However, over time histone modifications are added, making cell fate more defined and
the cell mature. Previous studies have demonstrated an extensive landscape of activating,
repressing, and bivalent chromatin marks in mature α-cells [11]. Furthermore, loss of
normal DNA methylation in mature β-cells leads to loss of cell fate, derepression of Arx,
and conversion into an α-cell fate [12]. Experiments examining histone modifications
and other chromatin marks will determine the nature of these marks, if there are
differences throughout the maturation process, and if these differences correlate with
maturing α-cells. α-cell specific characterization and ablation of each mark during
development as well as in mature α-cells will greatly clarify this issue.

Does Arx play multiples roles in specification and maintenance of α-cells?
Using a mouse model with an expansion mutation in the first polyalanine tract of
Arx, I demonstrated a reduced, but present, pancreatic α-cell population. α-cell
specification appears correct, with no misexpression of other endocrine hormones or βcell transcription factors. These data suggest that Arx plays a dual role during
specification in which it not only activates α-cell fate, but also leads to repression of other
non-α-cell fates. While an expanded form of Arx is not able to allocate normal numbers
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of α-cells (activation of α-cell fate), it is able to repress non-α-cell fates, resulting in
proper specification of a subset of α-cells.
Future experiments utilizing other non-null mutations of Arx that differentially
affect α-cell function will help clarify and elucidate these roles. Human neuronal studies
have classified a wide range of Arx mutations that differentially affect Arx's functional
abilities during neuronal development [13]. Exploring these mutations and the resulting
pancreatic phenotypes will further elucidate the role(s) of Arx during α-cell development.
In addition, chromatin immunoprecipitation (ChIP) experiments are essential to identify
direct targets of Arx. Since Arx predominantly functions as a repressor, and is also
thought to repress β-cell fate, likely targets include β-cell specific transcription factors,
such as Pdx1 and Pax4 [14,15]. These ChIP experiments will determine if each role of
Arx is due to direct repression/activation of Arx at a gene promoter or the indirect result
of Arx activity in endocrine α-cells. Finally, co-immunoprecipitation experiments will
determine if Arx is interacting with other co-repressors to exert its transcriptional
regulation in endocrine progenitors and newly created α-cells. Neuronal studies have
demonstrated Arx association with the co-repressors Tle1 and CtBP, leading to increased
transcriptional repression ability [14,16]. Studies examining these potential associations
during endocrine development will determine their role in the specification of α-cells.
Together, these experiments will clarify the function and mechanism(s) of Arx during αcell development.
Once the role(s) of Arx during α-cell development is understood, this knowledge
can be expanded to the role of Arx in maintenance of α-cell fate. My data demonstrate
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that Arx is necessary for α-cell fate maintenance. It would be interesting to explore the
targets and co-factors of Arx in the adult α-cell and determine if they are similar during
embryogenesis and postnatal life, or if there are important changes. This knowledge
would illustrate key differences between neonatal and mature α-cell fate maintenance.
Factors expressed in mature α-cells, but not during development, are likely to be
important in maintenance of cell fate. These studies will help expand the knowledge of
Arx in α-cells as well as how the endocrine pancreas is specified and maintained in
general.

Novel therapies for Type II Diabetes utilizing Arx in α-cells
During embryogenesis, endocrine cells are plastic and immediately lose cell fate
upon disruption of the proper transcriptional program [15]. However, as these cells
mature they become less plastic, and disruptions in the transcriptional program do not
immediately result in striking phenotypes [17]. In line with this, ablation of Arx in
mature α-cells does not result in a rapid or complete loss of α-cell fate. Instead, Arxablated α-cells appear to slowly lose cell identity and take on an α-β-cell hybrid fate that
secretes insulin in response to both α and β stimuli. Other cellular processes may make it
difficult for mature α-cells to quickly and completely abandon their determined cell fate.
Previous studies have illustrated the extensive chromatin landscape in mature α-cells
[18]. This landscape, combined with the normal transcriptional program, likely maintains
cell fate even upon transcriptional disruptions.
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Novel therapies for type II diabetes could emphasize decreased Arx expression
combined with additional stimuli to transdifferentiate mature α-cells into functional,
physiologically correct β-cells. Previous studies have demonstrated that upon total
ablation of β-cells, mature α-cells can spontaneously convert into functional β-cells [19].
Future experiments combining ablation of Arx with other pancreatic stressors or ablation
of chromatin marks would extend the observed adult phenotype and bring the field closer
to innovative treatments for type II diabetes. Furthermore, these experiments will extend
the field's knowledge of cell fate maintenance and its limits.

Summary
The goal of this dissertation was two-fold: (1) to determine the role of Arx in
maintenance of neonatal and mature endocrine α-cells, and (2) to characterize the effect
of a non-null polyalanine expansion mutation on normal α-cell specification and
maintenance. Overall, these results expand the previously described role of Arx in the
early specification of α-cells. The data presented here demonstrate that Arx is also
necessary for maintenance of α-cell fate, and plays a dual role during specification
through the activation of α-cell fate and repression of non-α-cell fates.
Together these studies significantly contribute to the field in multiple ways. First,
I demonstrated a novel role for Arx in α-cell fate maintenance, which can be utilized for
novel treatments of type II diabetes. Additionally, the discovery of dual roles for Arx
during α-cell specification raises the possibility that additional transcription factors are
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playing similar roles in other endocrine cell types. Finally, the loss of α-cell fate
maintenance during long-term ablation of Arx demonstrates that while mature pancreatic
islet cells may be able to function normally in the short-term upon loss of Arx, over time
even mature endocrine cells can lose their cell identity. Overall, these data expand the
field’s knowledge regarding normal α-cell specification and maintenance, and provide an
attractive avenue for future transdifferenation studies to develop novel treatments for type
II diabetes.
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